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INTRODUCTION 
 
 
Infection with Human Immunodeficiency Virus (HIV) and its end 
stage, Acquired Immunodeficiency Syndrome (AIDS) is the major public 
health challenge of our times, with over 25 million persons already dead and 
over 50 million living with HIV/AIDS, the majority of whom, without access 
to therapy. 
 
 
 According to Global HIV/AIDS Report 2016 by WHO, Prevalence of 
HIV/AIDS worldwide is estimated by WHO to be about 36.7 million. 
Incidence in the year 2015 was 2.1 million. Mortality due to HIV/AIDS-related 
illness in the year 2015 was 1.1 million ([1]WHO, Global statistic 2016). 
 
According to NACO, Prevalence of HIV/AIDS in India was 21.17 lakhs 
in 2015. Incidence rate was 86 thousands, which is 24 % of worldwide 
incidence and around 3.5 thousand HIV –positive pregnant women. India has 
the third largest HIV/AIDS incidence rate in the world. Mortality due to AIDS 
related illness was 67.6 thousand ([2]NACO, HIV/AIDS Statistic 2015 ). 
 
Psychiatric co morbidity in HIV/AIDS is common. Prevalence of mental 
illness has been found to be about 45% in people with HIV/AIDS, while some 
studies give a prevalence of mood disorder to be even up to 24 % including 
major depressive disorder 19% and adjustment disorder 7%, anxiety disorder 1 
%,substance use disorders 17% and psychotic disorder 1 %  ([3]Naresh 
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Nebhinanai et al,2011). During the course of illness, upto 85% of HIV – 
seropositive individuals report some depressive symptoms and upto 50% 
experience major depressive disorder ([4]J.Hampton Alkinson et al, 2018). 
Psychiatric co morbidity and substance abuse in HIV/AIDS have been 
associated with poor compliance, negative outcome of HIV, defaulter, 
resistance, destructive forms of HIV, greater HIV transmission, greater 
mortality and adverse drug reactions. 10% of  HIV/AIDS estimated to be due 
to alcohol ([5]David J.Dausey et al, 2003). Psychopathology may have impact 
on treatment adherence, quality of life, social and adaptive functioning and 
possibly HIV – illness progression ([6]Robinson and Quaqish 2002). 
Neuropsychiatric phenomena occurring during the course of HIV infection and 
AIDS can broadly be considered under neurobiological, psychobiological and 
psychosocial aspects. 
 
 
 In a meta analysis of published studies, [7]Ciesla and Robert (2001) 
found that people with HIV were almost twice as likely as those who are HIV 
– Seronegative to be diagnosed with major depressive disorder and that 
depression was equally prevalent in people with both symptomatic and 
asymptomatic HIV. Life time prevalence rates of anxiety disorders are higher 
in the HIV clinical population as a whole than in the general population 
([8]Blalock et al 2005). Initial symptoms of HIV infection are 
neuropsychological in 10% to 30% of cases ([9]Lezak – 1995). These 
phenomena can be the result of direct infection of the central nervous system 
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with HIV, opportunistic infections that occur in the central nervous system, 
individual psychological reactions to HIV disease and its consequences, the 
social implications of the disease and side effects of medications taken to 
manage the disease 
 
 NEED OF STUDY: 
 Psychiatric co morbidity in HIV/AIDS is an important factor in 
determining the course and outcome of HIV/AIDS and is associated with 
treatment follow-up factors like defaulting and poor compliance. It becomes 
important to assess the prevalence and severity of psychiatric disorders in 
people with HIV/AIDS and its association with various sociodemographic 
factors and disease related factors. Proper identification and treatment of 
psychiatric co morbidity will help improve patient adherence and quality of life 
and illness outcome in HIV/AIDS. 
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AIM 
• To assess the prevalence of psychiatric illnesses in people undergoing 
treatment for HIV/AIDS. 
 
OBJECTIVES 
• To assess the association between psychiatric co morbidity and different 
sociodemographic factors (age, gender, education) and disease related 
factors (duration of illness, stages of HIV/AIDS,  CD4 count, HIV-TB 
and other co infections and other opportunistic infections) 
• To assess the relationship between psychiatric co morbidity and 
treatment follow-up factors like poor adherence and history of 
defaulting. 
• To assess the support systems, functional level in relation to psychiatric 
illness.  
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REVIEW OF LITERATURE 
 Human immunodeficiency virus infection, and acquired immune 
deficiency syndrome (HIV/AIDS) is a range of conditions caused 
by infection with the human immunodeficiency virus (HIV).[10] HIV is spread 
mainly by unprotected sexual intercourse,  HIV infected blood 
transfusions, HIV contaminated needles, and from mother to child 
through pregnancy, delivery, or breastfeeding.[11]., Following early infection, 
a person might not notice any symptoms or might experience a short period 
of influenza-like illness. Usually, this is followed by a prolonged period with 
no symptoms. As the infection progresses, it interferes with the immune 
system, increasing the risk of developing common opportunistic infections 
such as tuberculosis, as well as other infections, and tumors that may rarely 
affect people who have working immune systems.[12] These late stages of 
infection are referred to as acquired immunodeficiency syndrome (AIDS). This 
stage is often also associated with unexplained weight loss.[13]  
 AIDS was first recognized in the US in 1981 with reports of 
unexplained opportunistic infections, including Pneumocystis jirovecii 
(formerly Pneumocystis carinii), pneumonia and Kaposi’s Sarcoma (KS) 
among homosexual men in New York and San Francisco ([14]Cleghorn, 
Reitzfr, and Gallo; 2000). 
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 The first case of HIV infection in India was diagnosed among 
commercial sex workers in Chennai, Tamil Nadu, 1986. 
 
 HIV / AIDS is a major public health problem all over the world. The 
overwhelming majority of HIV infected people, more than 90%, live in the 
developing world and most of them do not even know that they are infected. 
 This epidemic killed about 3 million people all over the world in the 
year 2004. Globally more than 40 million people are infected with HIV 
([15]Training Module on continuum of care for health care provider 2005 
TNAIDS control society). 
 HIV is a retrovirus that primarily infects components of the 
human immune system such as CD4- T cells, macrophages and dendritic cells. 
It directly and indirectly kills CD4- T cells. HIV is a belongs to 
 genus Lentivirus.  HIV is transmitted as single-stranded, positive-sense, 
enveloped RNA virus. After enters into the target cell, the 
viral RNA genome is converted into double-stranded DNA by a virally 
encoded reverse transcriptase that has transported along with the viral genome 
in the virus particle. The resulting viral DNA is then enters into the cell 
nucleus and integrated into the cellular DNA by a virally 
encoded integrase and host co-factors. After entered, the virus may 
become latent, allowing the virus and its host cell to stay away from detection 
by the immune system. Meanwhile, the virus might be transcribed, producing 
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new RNA genomes and viral proteins that are packaged and released from the 
cell as new virus particles that begin the replication cycle.  [16]  
 HIV is identified to spread between CD4 T cells by two parallel 
routes: cell-free spread and cell-to-cell spread.  In the cell-free spread, virus 
particles comes from an infected T cell, enter the extracellular fluid and then 
infect another T cell following a chance encounter. [17] . HIV may also spread 
by direct transmission from one cell to another by a process of cell-to-cell 
spread. [18]. These peculiar spreading mechanisms of HIV contribute to the 
virus's ongoing replication against antiretroviral therapies. [19]  
TYPES OF HIV   
 It has two types: Human ImmunodeficiencyVirus-1 and Human 
Immunodeficiency Virus-2. HIV-1 is the virus that was first discovered. It is 
highly infective and more virulent, and is the cause of the majority of HIV 
infections globally[20]. Compared with HIV-1, HIV-2 has low infectivity 
implies that only minor number of people exposed to HIV-2 will be infected 
per exposure. Because of its relatively reduced level of capacity for 
transmission, HIV-2 is largely confined to West part of Africa. [21]  
  MODE OF TRANSMISSION 
 
 HIV is present in blood, semen, cervical and vaginal secretions and to 
a lesser extent in saliva, tears, breast milk and the cerebrospinal fluid of those 
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who are infected (Sadock and Sadock, 2003)[22]. The modes of transmission 
include heterosexual and homosexual contact, vertical transmission, and 
instrumental transmission, which involves introduction of HIV – contaminated 
fluids or materials into the body by means of needles, blood products or 
various medical accidents. Receptive fellatio involving ejaculation of HIV – 
infected semen is another potential mode, but the actual risk is not known. 
Kissing is not considered a risk unless there is extensive oral disease with open 
sores. Worldwide, the sexual mode of transmission is the most important 
(Sadock & Sadock, 2000)[23]. 
 The chance of becoming infected after a single exposure is relatively 
low : 0.8 to 3.2% in unprotected receptive anal intercourse, 0.05 to 0.15% with 
unprotected vaginal sex, 0.32% after puncture with an HIV – contaminated 
needle and 0.67% after using a contaminated needle to inject drugs. 
  WINDOW PERIOD 
 The window period is time between exposure to HIV infection and the 
point when the test will give an accurate result. During the  period a person can 
be infected with HIV and be very infectious but still test HIV negative. The 
window period for a 4th generation antigen/antibody test is four weeks. At this 
time 95% of infections will be detected . There is a three month window period 
after exposure to HIV infection, for the confirmatory result to detect more than 
99.9% of infections. 
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DIAGNOSIS OF HIV INFECTION    
 HIV tests are commonly used to detect the presence of the human 
immunodeficiency virus (HIV), in serum, saliva, or urine. The standard 
screening test for HIV infection is the detection of anti-HIV antibodies using 
an enzyme immunoassay (EIA). This test is highly sensitive (>99.5%) and is 
quite specific. Most commercial EIA kits are able to detect antibodies to both 
HIV-1 and 2 and many also detect the HIV core antigen p24. The Western blot 
detects antibodies to HIV antigens of specific molecular weights. Antibodies to 
HIV begin to appear within 2 weeks of infection, and the period of time 
between initial infection and the development of detectable antibodies is rarely 
>3 months. Plasma p24 antigen levels rise during the first few weeks following 
infection, prior to the appearance of anti-HIV antibodies.  
  HIV can be cultured directly from tissue, peripheral blood cells, or 
plasma, but this is most commonly done in a research setting. HIV genetic 
material can be detected using reverse transcriptase PCR (RT-PCR), branched 
DNA (bDNA), or nucleic acid sequence–based assay (NASBA). These tests 
are useful in pts with a positive or indeterminate EIA and an indeterminate 
Western blot. They turn positive early in infection and will usually be positive 
in pts in whom serologic testing may be unreliable (such as those with hypo 
gammaglobulinemia). 
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Antigen/antibody combination tests - A combination, or 4th generation 
assay, is designed to detect both the p24 antigen and HIV antibodies in a single 
test. Combination tests can detect HIV as early as 2–6 weeks after 
infection,and are recommended in laboratory testing.[24](Harrison, 2016) 
STAGES OF  HIV/AIDS   
 The WHO clinical staging of HIV/AIDS for HIV- infected adults and 
adolescents into one of four hierarchical clinical stages ranging from stage 1 
(asymptomatic) to stage 4 (AIDS). Patients are assigned to a particular stage 
when they demonstrate at least one clinical condition in that stage’s criteria. 
Patients remain at a higher stage after they recover from the clinical condition 
which placed them in that stage . 
 Stage 1: Patients who are asymptomatic or have persistent generalized 
lymphadenopathy (lymphadenopathy of at least two sites [not including 
inguinal] for longer than 6 months) are categorized as being in stage 1, where 
they may remain for several years . 
 Stage 2:  Even in early HIV infection, patients may demonstrate 
several clinical manifestations. Clinical findings included in stage 2 (mildly 
symptomatic stage) are unexplained moderate weight loss of less than 10 
percent of total body weight and recurrent  respiratory tract infections (such as 
sinusitis, tonsillitis, bronchitis, otitis media, and pharyngitis), as well as a range 
of dermatological conditions including herpes zoster , angular cheilitis, 
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recurrent oral ulcerations, papular pruritic eruptions, seborrhoeic dermatitis, 
and fungal nail infections . 
 Stage 3 :  As disease progresses, additional clinical manifestations 
may appear. Those encompassed by the WHO clinical stage 3 (the moderately 
symptomatic stage) category are severe weight loss of greater than 10 percent 
of total body weight, chronic (more than 1 month) unexplained diarrhea, 
pulmonary tuberculosis, unexplained persistent fever (above 37.5 C 
intermittent or constant for longer than one month) and severe systemic 
bacterial infections including pneumonia, pyelonephritis, empyema, 
pyomyositis, meningitis, bone and joint infections, and bacteremia.  
Mucocutaneous conditions, including recurrent oral candidiasis, oral hairy 
leukoplakia, and  acute necrotizing ulcerative stomatitis, gingivitis, or 
periodontitis, and unexplained anemia (less than 8g/dl), neutropenia (less than 
0.5 x 109/l) and or chronic thrombocytopenia (less than 50 x 109/l)  may also 
occur at this stage . 
 Stage 4: The WHO clinical stage 4 (the severely symptomatic stage) 
which includes all of the AIDS-defining illnesses. Clinical manifestations for 
stage 4 disease will allow presumptive diagnosis of AIDS to be made based on 
clinical findings alone are HIV wasting syndrome, Pneumocystis 
pneumonia (PCP), recurrent severe bacterial pneumonia, extrapulmonary 
tuberculosis, HIV encephalopathy, CNS toxoplasmosis, chronic (more than 1 
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month) or orolabial herpes simplex infection, esophageal candidiasis, and 
Kaposi’s sarcoma . Other conditions that should arouse suspicion that a patient 
is in clinical stage include cytomegaloviral (CMV) infections (CMV retinitis or 
infection of organs other than the liver, spleen or lymph nodes), 
extrapulmonary cryptococcosis, disseminated endemic mycoses (e.g., 
coccidiomycosis, penicilliosis, histoplasmosis), cryptosporidiosis, isosporiasis, 
disseminated non-tuberculous mycobacteria infection, tracheal, bronchial or 
pulmonary candida infection, visceral herpes simplex infection, acquired HIV-
associated rectal fistula, cerebral or B cell non-Hodgkin lymphoma, 
progressive multifocal leukoencephalopathy (PML), and HIV-associated 
cardiomyopathy or nephropathy . Presence of these conditions unaccompanied 
by the AIDS-defining illnesses, however, should prompt confirmatory 
testing.[25] (WHO clinical staging, Jennifer L.weinberg et al, 2010) 
TESTS TO STAGE DISEASE  OF  HIV/AIDS  
 There are several tests used to determine the stage of  HIV/AIDS. 
These tests include: 
• CD4 T cell count: CD4 T cells are white blood cells that are specifically 
targeted and destroyed by HIV. Even patient  have no symptoms, HIV 
infection progresses to AIDS when your CD4 T cell count dips below 200. 
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• Viral load (HIV RNA). This test measures the amount of virus in patient 
blood. A higher viral load has been linked to a worse outcome. 
• Drug resistance. Some strains of HIV are resistant to medications. This 
test helps to determine if  patient specific form of the virus has resistance and 
guides treatment decisions. 
MANAGEMENT OF HIV/AIDS  
 The treatment of HIV/AIDS typically includes the use of 
multiple antiretroviral drugs in an attempt to control HIV infection. There are 
numerous classes of antiretroviral agents that act on different stages of 
the HIV life-cycle. The use of several antiretroviral  drugs that act on different 
HIV viral targets is known as highly active antiretroviral therapy (HAART). 
HAART decreases the patient's overall burden of HIV, maintains function of 
the immune system, and prevents many HIV opportunistic infections that often 
lead to death.[26] 
 There are many classes (mainly six classes) of ARV drugs, which are 
commonly used in combination, to treat HIV infection. Antiretroviral (ARV) 
drugs are generally classified by the stage of the retrovirus life-cycle that the 
drug inhibits. Usual combinations include two Nucleoside reverse transcriptase 
inhibitors (NRTI)  along with one Non-Nucleoside reverse transcriptase 
inhibitor (NNRTI), protease inhibitor (PI) or Integrase inhibitors [27]. 
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 ENTRY INHIBITORS OR FUSION INHIBITORS: 
  Its  mainly interfere with binding, fusion and entry of  HIV to the host 
cell by blocking one of numerous targets.   Maraviroc and Enfuvirtide are the 
example currently available in this class.  
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND 
NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS: 
 These  drugs mainly inhibit reverse transcription. Examples of mainly 
used NRTIs include zidovudine, lamivudine, abacavir, emtricitabine, 
and tenofovir. (Eddy Arnoid,et al,2013). Non-nucleoside reverse transcriptase 
inhibitors (NNRTI) mainly inhibit reverse transcriptase by binding to 
an allosteric position of the enzyme; NNRTIs act as non-competitive 
inhibitors of reverse transcriptase.  NNRTIs can be additionaly classified into 
first generation and second generation NNRTIs. 1st generation NNRTIs 
include nevirapine and efavirenz. 2nd generation NNRTIs are etravirine  and 
 rilpivirine.[28], [29].  
INTEGRASE INHIBITORS:  
 It also called as integrase nuclear strand transfer inhibitors or INSTIs 
and its mainly inhibit the viral enzyme integrase, which is accountable 
for integration of viral DNA into the DNA of the infected cell.  Example of 
integrase inhibitors are elvitegravir and dolutegravir [30].  
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PROTEASE INHIBITORS: 
 It inhibits the viral protease enzyme which is necessary to produce 
mature virions upon budding from the host membrane. predominantly, these 
drugs prevent the cleavage of gag and gag/pol precursor proteins[31]. 
Examples are lopinavir, ritonavir, indinavir, nelfinavir, and amprenavir. 
THE INTERACTION OF PHYSICAL AND PSYCHIATRIC 
MORBIDITIES: 
          Psychiatric and physical diseases or disorders can influence each other 
through many mechanisms. One is through direct actions on physiological 
systems like neuroendocrine and immune systems. Another is through health 
behaviour. Patients with chronic diseases have multiple burdens like pain, 
reduced quality of life, premature death, financial costs and emotional trauma 
to the family members. Mood disorder has a lifetime prevalence of 8.9% to 
12.9% and a six month prevalence of 5.8% to 9.4% in chronic diseases. About 
20% of patients with physical disease suffer from major depression. It is a 
known fact that, sometimes, it may be difficult to determine if a somatic 
symptom is  associated with the physical illness or the psychiatric illness[32] 
(Lustman, P. J. 1995, Lustman, P. J. 2000, DiMatteo, M. R. 2000). 
 Adherence rate for long term medications is estimated to be about 
50%. That is, about half of patients supposed to take drugs on term for physical 
illnesses, stop taking them. Depression has an important role in this behaviour. 
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Studies have found that depression is associated with poor adherence rate with 
medications for physical illnesses. Patients with depression were found to be 
three times more likely to have poor adherence than those without depression. 
Moreover, treatment of depression and anxiety in patients with physical illness 
can lead to better outcomes regarding their physical illness. This has been 
observed in patients with diabetes in various studies. Substance use has also 
been associated with poor compliance with treatment[34] (Doherty, A. M., 
2013). 
PSYCHIATRIC ASPECTS OF HIV INFECTION AND AIDS 
 Neuropsychiatric phenomena occurring during the course of HIV 
infection and AIDS can broadly be considered under neurobiological, 
psychobiological and psychosocial aspects. These phenomena can be the result 
of direct infection of the central nervous system with HIV, opportunistic 
infections that occur in the central nervous system, individual psychological 
reactions to HIV disease and its consequences, the social implications of the 
disease and side effects of medications taken to manage the disease. Thus, the 
broad range of mental health problems associated with HIV infection includes 
not only understandable emotional reactions to the illness, but also frank 
psychiatric disorders and neuropsychiatric syndromes. 
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Research has been carried out on the psychological status of people with 
HIV infection, including those at different stages of the illness, such as at the 
time of HIV testing, during asymptomatic and symptomatic stages of the 
illness. Notification of a positive test result is usually associated with severe, if 
transient, distress. Common diagnosis given to asymptomatic individuals 
referred to mental health services are adjustment disorder, major depression 
and other forms of depression, substance misuse, panic disorder and 
personality problems. A large number of symptomatic HIV patients present 
with depression [35],[36](Perry and Tross, 1984; Dilley et al, 1985), while 
other common diagnosis in this group includes organic brain syndromes. 
 A number of studies have assessed the prevalence of psychiatric 
disorders in HIV positive patients[37],[38],[39],[40] (Seth 1991; Faulstich 
1987; Maj 1994). King et al (1989)[41] reported that 31% of a sample of 192 
outpatients with HIV  infection and AIDS had significant psychiatric problems. 
In a study done by[42] Lykestos et al (1994) on HIV positive patients attending 
a medical outpatient clinic, 54% had a psychiatric disorder, with an additional 
22% diagnosed with substance use disorder. Lluch et al, on evaluating 
psychopathology in an inpatient sample of 25 AIDS patients, found that 80% 
had a psychiatric diagnosis, of which, the greatest number showed depressive 
symptoms. A study done in Spain by Ayuso et al [43](1996) on AIDS patients 
detected psychoactive substance use to be the principal diagnosis followed by 
adjustment disorder. As most available studies had been done on western 
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populations, the WHO in 1994 implemented a cross-cultural venture called the 
WHO Neuropsychiatric AIDS study. The overall prevalence of current mental 
disorder was significantly higher in seropositive compared to seronegative 
patients in two of the five centers in the study. Probably one of the first 
reported studies on psychiatric morbidity in HIV infected individuals in India, 
by Jacob et al,[44] documented an overall psychiatric morbidity of 26.1 %. 
 Some other studies done by Atkinson et al (1988)[45] and Williams et 
al (1991) [46] did not find a significant difference between HIV positive and 
negative controls with respect to prevalence of psychiatric morbidity. 
 Factors associated with the development of psychiatric disorders in 
HIV positive individuals have been studied: 
 HIV related factors - mental health symptoms are more likely to 
occur at two stages; i.e., when the person is given a diagnosis of HIV infection 
and when physical symptoms develop or worsen[47],[48] (Davis et al 1995; 
Holt et al 1998).  
 Personality factors - there is some evidence to show that people with 
personality disorders, in particular those with borderline or antisocial 
personality disorder are at a greater risk of acquiring HIV infection 
[49],[50](Johnson et al 1996; Golding & Perkins 1996). It is suggested that 
people with personality disorders have less effective coping styles. 
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Past psychiatric history-  person with  psychiatric distress has high 
vulnerability  to Infection with HIV [51],[52] (Dew et al, 1990; Catalan et al, 
1992). 
 Social support - individuals lacking in adequate social support 
usually report greater levels of psychological distress[53] (Catalan et al, 1995; 
Katz et al 1996) 
 Adverse life events - multiple bereavements, loss of supports, 
survivor's guilt and concerns about one's own health can conspire to make what 
is already a difficult situation, extremely hard to cope with, leading to 
unresolved and complex grief reactions [54],[55](Sherr et al, 1995; Fishman 
and Perry, 1989). 
 Sociodemographic characteristics - Older individuals may be at a 
greater risk for cognitive impairment and dementia (Catalan et al, 1995). 
Injecting drug users have the poorest psychological status, often having 
experienced social and psychological difficulties prior to acquiring the 
infection[56] (Gala et al, 1993). 
PSYCHIATRIC DISORDERS AND HIV 
ACUTE STRESS REACTIONS 
 Psychological reactions to the diagnosis of HIV infection resemble 
those commonly described in response to the diagnosis of cancer or other life 
threatening diseases. However, in view of the specific psychosocial dimensions 
relevant to HIV, subjects receiving the diagnosis are suddenly confronted not 
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only with the likelihood of developing a disease with a very poor prognosis, 
but also with various other issues: revealing their homosexuality / drug abuse 
to family, friends and colleagues; dealing with the fear of partners, friends and 
public; avoiding transmitting the infection to others and protecting themselves 
from opportunistic infection[57],[58] (Christ et al, 1988; Miller 1988). For all 
the above reasons, it is not surprising that acute stress reactions have been 
reported in upto 90% of subjects with a recent diagnosis of HIV (WHO, 1988). 
 Acute stress reaction may occur in any phase of the infection, with 
various changes in the person's clinical state. However, it is most common 
immediately after the diagnosis. It has also been found to occur most 
frequently in subjects lacking a partner or living in a rural environment 
according to reports from Germany [59](Seidl & Goebel, 1987), and also to be 
more common in homosexuals. Apart from clinical features of confusion, 
bewilderment, derealization and sleep disturbances are noted initially 
following the diagnosis; other emotional and behavioural reactions may 
include anger, withdrawal, guilt, denial, fear, despair[60],[36],[61] (Morin et 
al, 1984; Dilley et al 1985, Miller 1995). Management focuses primarily on 
preventive measures such as pretest and post test counseling.  
  
21 
 
ADJUSTMENT DISORDERS 
 This is characterized by a morbid (that is excessive in length and/or 
intensity) response to the diagnosis of HIV infection or AIDS, or more 
generally to the stress associated with the disease. The clinical features may be 
characterized by depression, anxiety or obsessions and compulsions, and the 
disorder may last many months (WHO, 1988). Adjustment disorder has been 
reported to be the most frequent diagnosis in patient's with ARC or AIDS 
referred for psychiatric consultation[36],[62],[63],[64] (Dilley et al, 1985; 
Tross et al, 1986; Rundell et al, 1988; Schaerf et al 1989). 
 The disorder can be conditioned by several factors: subject's coping 
strategies[65] (Namir et al, 1(87), subjects who have internalized social non 
acceptance of drug abuse or homosexuality leading to feelings of guilt and self 
depreciation[66],[58] (Hays & Lyles, 1986; Miller, 1988), previous history of 
psychiatric disorders[62] (Holland & Tross, 1985), family estrangement[58] 
(Miller 1988), over concern over the impact of the illness on loved ones, 
financial difficulties, and poor social support[67] (Zich and Temoshok 1987). 
 Management involves behavioural and cognitive psychotherapy on an 
individual or group basis, involving partners or family members as patients 
judge appropriate [58](Miller, 1988). Pharmacological treatment of depressive 
or anxiety symptoms may be required. 
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MOOD DISORDERS 
1) DEPRESSIVE SYNDROMES: 
 A depressive syndrome not fulfilling the ICD-10 or DSM- IV criteria 
for depressive episode may occur at any point in the course of HIV infection 
(WHO, 1988). Major depressive disorder has been reported in subjects with 
HIV infection but estimates concerning its prevalence have been quite 
divergent. In a study of admitted AIDS patients done by Perry and Tross 
(1984)[35], 82.7% showed mood disturbance with 17.3% fulfilling criteria for 
major depressive disorder. In hospitalized patients, this rate may be higher and 
approach 40%. Rundell et al (1988)[63] after reviewing records of 111 HIV 
positive subjects seen at a Medical Air Force Centre in Texas, found major 
depressive disorder in 3.6% of the sample. Schaerf et al (1989)[64] found a 
prevalence of 7% in a sample of AIDS patients, which was comparatively less 
than the prevalence of depressive disorders in a sample of general hospital 
consultations. Similar low rates of current major depression in men with AIDS 
was reported by Rabkin et al 1997[68], who found overall rates of 5-10% with 
no significant difference between HIV negative men, HIV positive men 
without AIDS and men with AIDS defining conditions. 
 Inspite of these studies, others have reported rates of current major 
depression in HIV populations elevated two folds above those in healthy 
community samples and usually in the range found with other chronic medical 
illnesses [45](Atkinson et al 1988, Perry) 1990, [46]William et al, 1991. In 
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view of these vastly differing results Jeffrey Ciesla (2001)[69] conducted a 
meta-analysis of 10 studies conducted from 1988 to 1998, which compared the 
rates of current major depression between HIV positive and HIV negative 
groups. Though most of these studies concluded that the infection was not 
associated with a higher rate of the disorder, the results of the meta-analysis 
showed that the frequency of major depressive disorder was nearly 2 times 
higher in HIV positive than HIV negative persons with no relation to sexual 
orientation or disease stage. 
 The relationship between depression and disease progression in HIV 
has also been studied. A 10 year multicentre AIDS Cohort study by Lykestos et 
al (1996)[70], showed a dramatic sustained rise in depressive symptoms as 
AIDS develops, with prior depression, HIV disease related factors and 
psychiatric stressors contributing to this risk. 
Major depressive disorder in HIV may be interpreted in several ways: 
o It may result from psychosocial problems related to the illness. 
o May be directly related to HIV infection of the brain, in particular   
the predilection of the Virus for limbic areas, believed to control 
emotional experience. 
o Predisposing factors in a vulnerable subject. 
o From chance association. 
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o May result from secondary effects of the infection i.e., 
opportunistic infections or neoplasms [35](Perry & Tross, 1984), 
or use of antineoplastic drugs [71](Volberding et al 1985). 
 It is important to emphasize that depressive symptoms may be difficult 
to differentiate from some manifestations of AIDS Related Complex (fatigue, 
anorexia, weight loss, decreased libido) or of dementia (decreased memory and 
concentration). 
2) MANIC SYNDROMES 
 A few cases of hypomania or mania in subjects with HIV infection 
have also been described. The possible interpretations are similar to those 
proposed for acute psychotic disorder, with mania occurring either in the 
context of cognitive impairment[72],[73],[58]  (Gabel et al 1986: Schmidt & 
Miller, 1988), or in the absence of cognitive impairment [73],[74](Schmidt & 
Miller 1988; Buhrich et al, 1988). 
ANXIETY DISORDERS 
 Symptoms of anxiety determined by self report checklist tend to be 
higher in medically asymptomatic HIV positive patients than HIV negative at-
risk samples [75](Atkinson et al, 1989). But other studies have reported that 
anxiety disorders may be common in groups at high risk for HIV infection, 
irrespective of HIV status[76],[77] (Baer 1989; Perry 1990). Six month 
prevalence rates of generalized anxiety disorder in HIV positive men are in the 
ranges of 15-20 percent [78](Atkinson & Grant 1994). Rates of other anxiety 
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disorders do not appear to be markedly elevated [79],[77](William, 1991; Perry 
1990). Simple phobias and hypoactive sexual desire disorder have been 
reported[80] (Rundell & Brown 1990).  
ACUTE PSYCHOTIC DISORDERS 
  With evidence of cognitive impairment 
 Hallucinations (either visual or auditory) and delusions (either 
persecutory or grandiose) are not infrequent in patients with ARC or AIDS. 
They may occur in the context of cognitive impairment which may sometimes 
be subtle or fluctuating [81],[80],[82](Nurnberg et al, 1984; Rundell, 1990; 
Thomas & Szabadi, 1987) or they may be initially the only psychopathological 
manifestation. 
  Without evidence of cognitive impairment 
 Patients with asymptomatic HIV infection, AIDS Related Complex or 
AIDS, who developed acute psychotic disorders without any evidence of 
cognitive impairment throughout the episode, have been reported[83],[84],[74] 
(Thomas et al, 1985; Halevie-Goldman et al,  1987: Buhrich et al 1988). The 
interpretation for this has already been outlined under manic disorders. A 
specific vulnerability of dopaminergic systems in AIDS has been suggested by 
[85]Holland et al (1985). The predilection of HIV for the limbic system has 
also been discussed in connection with a case of catatonia in a HIV positive 
subject in whom PET scan showed increased blood flow in the right temporal 
cortex and basal ganglia[86] (Volkow et al, 1987). 
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 Though there have been numerous case reports of psychosis in HIV 
infection and AIDS with estimated rates of 0.1 to 5% [87],[88],[74](Sewell et 
al, 1994; Harris et al 1991; Buhrich 1988), accurate estimates of incidence and 
prevalence as compared to the general population is completely unknown[89] 
(Maj 1990). Treatment interventions studied in this group have found the 
response to neuroleptics to be favourable, but AIDS patients are highly 
susceptible to the extrapyramidal side effects of antipsychotic drugs. 
HIV DEMENTIA 
 The HIV virus being highly neurotrophic, neuropsychological 
abnormalities are commonly present in HIV infected individuals. Clinically 
apparent central nervous system disease occurs in at least 20-40% of AIDS 
patients[90] (Wolcott et al 1989). 
 HIV dementia is currently believed to be caused by the infection of the 
brain with HIV [91](Navia et al, 1986). The onset is usually insidious. Early 
symptoms can be subdivided into three groups: cognitive, behavioural and 
motor[91],[92] (Navia et al, 1986; Price et al 1988). Behavioural symptoms 
include apathy, reduced spontaneity and social withdrawal. Depression, 
irritability, emotional lability, agitation and psychotic symptoms can rarely 
occur. Estimates of the prevalence of HIV dementia varies according to the 
sample studied, the stage of illness and the criteria used for diagnosis. Janssen 
et al (1989) [93]reported that of the adults in his study, 6.5% had HIV 
dementia, and 3.0% were reported to have it as the only early manifestation of 
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AIDS. Previous estimates of the point prevalence of HIV dementia in AIDS 
patients ranged from 8-16% (WHO 1988). 
 As expected, the prevalence is found to be much higher in autopsy 
series of cases reported to neurologists, reaching the figure of 66% [92](Price 
et al, 1988). Neurological abnormalities have been reported in a substantial 
proportion of symptomatic HIV positive subjects, not showing the clinical 
picture of HIV dementia. Neurocognitive impairment in the asymptomatic 
phase of HIV infection remains controversial [94](Grant et al 1989). 
DELIRIUM 
 Delirium has been described both in relation to HIV dementia[92] 
(Price et al, 1988) and to the aseptic meningitis which may occur following 
infection. Its occurrence in AIDS patients may be related to hypoxia (from 
Pneumocystis carinii pneumonia) Cryptococcus meningitis, systemic 
infections, space occupying lesions of the brain (CNS lymphoma or brain 
abscesses due to toxoplasmosis), metabolic impairments and the use of 
psychotropic medications (especially tricyclic antidepressants, whose central 
anticholinergic activity seems to be more pronounced in such patients). 
 The syndrome usually develops over a short period of time (hours to 
days) with fluctuations in intensity over the course of a day. Complete 
recovery of delirium usually occurs at the time of seroconversion, but delirium 
superimposed on HIV dementia may aggravate its course [92](Price et al 
1988). 
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 Available estimates of the prevalence and incidence of HIV delirium 
in HIV infection are lacking.  
SUBSTANCE USE DISORDERS 
 Groups at highest risk for HIV infection also commonly have 
substance use disorders and alcohol dependence[45],[76] (Atkinson et al, 1988; 
Baer 1989). Though many alcoholics have a chronic history of substance use, 
alcohol use disorders may occur in some individuals due to the stress of the 
disease and physical disability. 
PERSONALITY DISORDERS 
 Perkins et al (1993)[95] assessed personality disorders in a HIV 
positive population and found the prevalence to be fairly high. Patients with 
personality disorders may experience greater dysphoria and are more likely to 
cope with the threat of AIDS in a dysfunctional way. 
OTHER AIDS RELATED PSYCHOPATHOLOGY 
 Delusions - It is well known that psychotic patients tend to incorporate 
in their delusions, topics that are of public interest. Several authors have 
described delusions of having contracted AIDS in patients suffering from 
psychotic depression, schizoaffective disorder or paranoid schizophrenia[96], 
[97],[98] (Rapaport & Braff, 1988; O'Brien, 1987; Shetty, 1988) with the most 
frequent occurrence in psychotic depression.  
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 Suicidal attempts by contracting AIDS[98],[99] (Francis et al 1985: 
Flavin et al 1986) – Highest risk in homosexual men who are depressed or 
alcoholic. 
 Factitious AIDS [100](Miller et ~ 1986)  
AIDS RELATED PSYCHOPATHOLOGY IN SUBJECTS WITHOUT 
HIV INFECTION 
 Hypochondriacal syndrome (the 'worried well') a syndrome marked by 
the persistent belief in the presence of HIV infection despite repeated negative 
serological tests and clinical examinations has been described by various 
authors[101],[58] (Forstein, 1984; Miller, 1988). 
   HIV AND TUBERCULOSIS: 
 HIV is one of the risk factors for developing tuberculosis. HIV/AIDS 
by itself is estimated to have lowered economic growth and reduced life 
expectancy by up to 50% in some countries. TB-HIV co-infection has been 
found to have a greater risk of common mental disorders (OR=1.7, 95% 
CI=1.1-2.9, p<0.05)[102] (Deribew, A., T, 2010). HIV positivity was also 
associated with increased risk for extraulmonary TB (OR=4.93, 95% CI = 
1.95-12.46)[13] (Yang Z, 2004). HIV positive patients with TB tend to have 
poorer TB outcome compared to those without HIV. About 88% of patients 
with TB who were not HIV seropositive had good TB outcome, while only 
73% of patients  with TB who were HIV seropositive had good TB outcome. 
The proportion of TB patients who died during treatment was more than three 
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times higher in those who were HIV positive compared to those who were HIV 
negative (11% vs 3.5%) (WHO, Global tuberculosis report 2015). In many 
countries, HIV/AIDS is considered even as a threat to national security (WHO,  
The World Health Report 2001). 
 Summarising, past studies show that HIV/AIDS is associated with 
significant psychiatric morbidity and that psychiatric morbidity in chronic 
medical conditions affect compliance and lead to poor outcome. Substance use 
disorders significantly increase the risk of HIV/AIDS, and also affect 
compliance with drug regimen.                                                                            
 
  
  
 
 
 
MATERIALS AND METHODS 
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METHODOLOGY 
STUDY DESIGN: 
 Cross sectional study 
PLACE OF STUDY: 
 Anti –Retroviral Therapy, Center,  Govt.Kilpauk Medical College 
DURATION OF STUDY: 
 6 months 
Sample size Calculation: 
 N=4pq/d*d  
N- Total Number sample size, p – prevalence, q – 100-prevalence, d-precision. 
 p = 45% (percentage of psychiatric morbidity in HIV/AIDS) 
             d = Absolute precision= 10%  
             Calculation N=4 x (0.45 x 0.55) / 0.1 x 0.1 = 99 
             Assuming 10 % non-response = 99 + 10 = 109; Rounding off = 109  
INCLUSION CRITERIA 
           1. HIV/AIDS, as diagnosed by a  physician. 
       2.Atleast one month passed since initiation of treatment 
       3.Currently on treatment 
       4.Age  between 18 and 60 yrs 
       5.Given consent for the study 
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 EXCLUSION CRITERIA 
  Acutely ill patients whom psychiatric interview is not possible  
  Patients who did not consent 
MATERIALS AND METHODS: 
 Our study is a cross sectional study conducted at ART CENTER, 
Government Kilpauk Medical College, chennai. A total of 109 consecutive 
patients attending the ART clinic in Govt. Kilpauk Medical College, fulfilling 
the inclusion and exclusion criteria were interviewed. Informed consent were 
obtained from those willing to participate.  
  All patients were diagnosed with HIV/AIDS  by consultant chest 
physicians .A semi structured socio demographic proforma (Name, age, pre 
ART/ART/no., gender, education, occupation, family income per month, 
marital status, type of family) and Kuppuswamy socioeconomic status scale 
were applied to participants. Information regarding disease related factors like 
duration of illness, stages of HIV/AIDS,cd4 count, H/O default, presence of 
TB coinfection and other opportunistic infections, ART drugs the patient is on, 
past history of psychiatric illness and family history of psychiatric illness were 
collected. Symptom Check List 90 (SCL-90) was used to screen for patients, 
ICD 10 guidelines were used for diagnosis of psychiatric disorders, Hamilton 
Depression rating scale (HAM-D 17) and Hamilton Anxiety rating 
scale (HAM-A) were used for assessing the severity of depressive and anxiety 
disorders respectively. Fagerstorm nicotine dependence test score and Alcohol 
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Use Disorder Identification Test (AUDIT) score were used to assess the 
severity of nicotine dependence and alcohol dependence respectively. 
ETHICAL APPROVAL 
 Ethical approval for this study was obtained from the Ethics 
committee, Government Kilpauk Medical College, Chennai 
TOOLS USED: 
1. A semi structured socio demographic proforma (Name, age, ART no, 
sex, education, occupation, socioeconomic status, social support, marital 
status, type of family, time interval between HIV diagnosis and 
treatment). 
2. Kuppuswamy socioeconomic status scale 
3. Symptom checklist-90 to screen the patients 
4. ICD 10 clinical and diagnostic criteria 
5. Hamilton rating scale for Depression  (HAM-D ) 
6. Hamilton rating scale  for Anxiety (HAM-A) 
7. Fagerstrom nicotine dependence test 
8. Alcohol Use Disorder Identification Test (AUDIT) 
9. Montreal cognitive assessment (MoCA)- for cognitive functions 
10. Multidimensional Scale of Perceived Social Support- for support system 
11. Morisky medication adherence – for medication adherence 
12. Karnofsky Performance Status Scale (KPS)  – for functional ability of 
the patients. 
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SYMPTOM CHECKLIST -90 REVISED 
 The Symptom checklist-90 is a self-report psychometric questionnaire 
published. It is used to assess a wide range of psychological problems and 
symptoms of psychopathology. It contains 90 items, yielding 9 scores along 
primary symptoms and 3 scores among global distress indices. The main 
symptoms that are assessed are depression, somatization, obsessive-
compulsive disorder, anxiety, interpersonal sensitivity, phobic anxiety, 
paranoid ideation, hostility and psychotism. The three universal distress indices 
are global wellness index, hardiness and symptom free. The internal 
consistency coefficient rating ranged from 0.80 for depression and 0.77 for 
psychotis(Pearson, 2016) It is one of the most commanly used measures of 
psychological distress in research and clinical practice. (John.M.Gottman et 
al,2009). 
HAMILTON RATING SCALE FOR DEPRESSION 
 The Hamilton rating scale for depression was developed in the 1950. It 
is a clinician administered scale and is one of the commanly used scales in 
psychiatry.  The scale was initially designed with 21 items. Later, 4 items 
(diurnal variation, de-realization, paranoid symptoms and obsessional 
symptoms) were dropped. Diurnal difference was considered as not being a 
measure of depression or its intensity. Now this is 17 items in the scale, though 
the original 21 items version is also occasionally used. In this study, we  were 
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used the 17 items version. The following  items are present in the scale: 
depressed mood, feeling of guilt, suicide, insomnia early, insomnia middle, 
insomnia late, work and activities, retardation, agitation, anxiety (psychic), 
anxiety(somatic), somatic symptoms (gastrointestinal), somatic symptom 
(general), genital symptoms, hypochondriasis, loss of weight and insight. Each 
item was scored on a three to five point scale (0-2 to 0-4). Individual scores 
were later summed up to give a total score. The scale had been shown to be 
sensitive over a wide range of depression severity in studies. The inter-rater 
reliability for the scale has found to be good (0.82) (Cicchetti DV et al., 1983). 
Internal consistency of the scale was also found to be 0.83. Validity of the 
scale range from 0.65 to 0.90 .Validity also extremely correlated with 
behavioral features, and somatic features account for about half of the total 
possible score in the scale. The maximum possible total score on the scale is 
52. (Hamilton M et al.,1960, Williams JP et al.,1988, Carroll BJ et al.,1973, 
Baer L et al., 2010). 
HAMILTON RATING SCALE FOR ANXIETY 
 The Hamilton rating scale for anxiety is designed to measure anxiety 
in patients already diagnosed with anxiety disorders. The scale is not intend to 
be a diagnostic tool. The scale is also not means for using disorders other than 
neurotic anxiety states. The scale consist of 14 items and is clinician 
administered. It takes for about 15 to 30 minutes to administer this scale. The 
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items in this scale are: anxious mood, insomnia, intellectual, depressed mood, 
tension, fears,  somatic (muscular), somatic (sensory), cardiovascular systems, 
respiratory systems, gastrointestinal systems, genitourinary systems, autonomic 
systems and behavior at interview. Each item was scored on a five point scale 
0 to 4. The scores were all added up to yield the total score. In addition to the 
total score, two subscales have been suggested-cyclic subscale and somatic 
subscale. A scale had been evaluated for reliability and had been found to have 
an inter-rater correlation of 0.89. Internal consistency ranges from 0.77 to 0.92. 
(Hamilton MA et al., 1959, Maier W et al.,1988, Baer L et al.,2010). 
ALCOHOL USE DISORDER IDENTIFICATION TEST 
 The alcohol use disorder identification test (AUDIT) was developed 
by the World Health Organisation as a simple method of screening for 
excessive drinking. It is one of the two scales recommended by the National 
Institute of Alcohol Abuse and Alcoholism (USA) for screening of alcohol 
related problems. It can be self administered or interviewer administered. It 
takes about 2-5 minutes to complete. There are 10 items in the scale that 
measure the following: 1) frequency of drinking, 2) typical quantity per day, 3) 
frequency of heavy drinking, 4) impaired control over drinking, 5) increased 
salience of drinking, 6) morning drinking, 7) guilt after drinking, 8) blackouts, 
9) alcohol related injuries, 10) others concerned about drinking. Each item is 
scored from 0-4 and the total score is added up. There are three domains in the 
AUDIT – hazardous alcohol use, dependence symptoms and harmful alcohol 
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use. Items 1-3 assess hazardous alcohol use, 4-6 assess dependence symptoms 
and 7-10 assess harmful alcohol use pattern. A cut off of 8 for problematic 
drinking was found to have a sensitivity of around 0.90, and specificity of 
around 0.80 across countries. It has been found to be sensitive and specific to 
alcohol use disorder. It has been found to have good reliability and validity 
across countries and population subgroups. Cronbach's alpha for internal 
consistency was found to be around 0.80. A high correlation coefficient of 0.78 
has been found between AUDIT and the CAGE questionnaire. It is also 
considered a useful tool for identifying people who would benefit from 
reducing their drinking even if they are not alcohol dependent. AUDIT score 
has been categorised in to four risk zones. Scores 0-7 fall in zone 1, scores 8-
15 fall in zone II, scores 16-19 fall in zone III and scores 20-40 fall in zone IV 
(Baer L 2010, WHO The alcohol Use disorders identification test 2001, Allen 
JP, 1997).  
KUPPUSWAMY SOCIOECONOMIC STATUS SCALE 
 Kuppuswamy socioeconomic status scale was a commonly used scale 
to assess the socioeconomic class of  study participants. It was published in 
1981 initially but modifications have been published frequently to account for 
the changing price index. It have three categories to be scored-head of the 
family educational level, the head of the family- occupation and income per 
month. Education was scored from 1 to 7, occupation from 1 to 10 and 
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monthly family income from 1 to 12. The total was added up. There were five 
socioeconomic classes that can be derived from the scale-upper, upper middle, 
middle/lower middle, lower/upper lower and lower. The scale requires 
modification from time to time because of the changing price index that affects 
the validity of the income per month subset in the scale (Kumar BR et al., 
2012, Sharma R et al., 2014, Patro BK et al., 2012). 
  MONTREAL COGNITIVE ASSESSMENT  
 Ziad Nasreddine was created, Montreal Cognitive assessment in 1996 
at Montreal, Quebec. It is a one page 30-point test, and needs around fifteen 
minutes to administered the test. MoCA scores range between 0 and 30. A 
score of 26 and above is considered to be normal. It assesses numerous 
cognitive domains. The short term memory recall test (5 points) involves two 
learning trials of 5 nouns and delayed recall after 5 minutes. Visuospatial 
abilities are assessed using a clock-drawing test (3 points) and a 3-dimensional 
cube copy test (1 point). Executive functions are assessed by using an 
alternation test adopted from the trial making B test (1 point), a phonemic 
fluency task (1 point) and a two – item verbal abstraction task (2 points). 
Attention, concentration and working memory are evaluated by using a 
sustained attention test (target detection using tapping; 1 point), serial 
subtraction test (3 points), and digits forward and backward  test (1 point each) 
language is assessed using a 3 –item confrontation naming test with low-
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familiarity animals (lion, camel, rhinoceros; 3 points), repetition of two 
syntactically complex sentences (2 points). Finally, orientation to time and 
place is assessed. (Nasreddine Z et al.,2005) 
MULTIDIMENSIONAL SCALE OF PERCEIVED SOCIAL SUPPORT 
 Numerous studies have demonstrated that social support as a buffer 
for psychological distress.  Zimet et al. developed   the Multidimensional Scale 
of Perceived Social Support, which have been commanly used in both clinical 
and non clinical samples. ( zimet et al., 1988), It is an attempt to measure 
social support, 
 The MSPSS is intended to assess the extent to which an individual 
perceives social support from many(mainly three) sources: Family (Items 3, 4, 
8, and 11), Friends (Items 6, 7, 9, and 12) and Significant others (Items 1, 2, 5, 
and 10). The MSPSS is a brief, easy to administer, and it is self reported 
questionnaire which contains 12 items rated on a seven point Likert-type scale 
with scores ranging from ‘very strongly disagree’ to very strongly agree. The 
MSPSS have proven to be psychometrically sound in diverse samples and to 
has good internal reliability and test-retest reliability, and robust factorial 
validity. 
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KARNOFSKY PERFORMANCE STATUS SCALE (KPS) 
 The Karnofsky Performance Status Scale is used to classify the 
patients to be   their functional impairment. This is also be used to compare 
effectiveness of different therapies and to assess the prognosis in individual 
patients. The lower the Karnofsky score, the poorer the survival for most 
serious illness. The Karnofsky Performance Score ranking runs from 100 to 0, 
where 100 is “perfect” health and 0 is death. Dr. David A. Karnofsky was 
described the scale in 1948. (Karnofsky et al)  
• 100- Normal; no evidence of disease, no complaints 
• 90- Able to carry out normal activity, minimal motor signs or symptoms 
of disease 
• 80- Able to do normal activity with effort, some signs or symptoms of 
disease. 
• 70- Able to cares for self and unable to carry on normal activity or to do 
active work. 
• 60- occasional assistance required, but able to care for most of his 
personal needs. 
• 50- considerable assistance required and needs frequent medical care. 
• 40- Disabled,needs special care and assistance. 
• 30- Severely disabled, hospital admission is needed although death not 
imminent’ 
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• 20- Very sick, hospital admission essential, active supportive treatment 
necessary. 
• 10- Moribund, fatal processes progressing quickly. 
• 0 - Dead. 
MORISKY’S MEDICATION ADHERENCE SCALE (MMAS) 
 The MMAS is a self-reported quesnairre, In this asked about 
medication- taking behavior in which the specific health issue is inserted for 
the health concern. The MMAS consists of four items with a scoring scheme of 
“yes”=0 and “No”=1. The items are summed to give a range of scores from 0 
to 4. 
  STATISTICAL ANALYSIS 
 Statistical analysis is to be done using computer software, to evaluate 
the prevalence of psychiatric illnesses in people undergoing treatment for 
HIV/AIDS will be given as percentage, Chi square test was used to assess the 
relationship between psychiatric co morbidity and different sociodemographic 
factors and disease related factors  (duration of illness, stages of 
HIV/AIDS,CD4 count, HIV-TB co infection), to assess the relationship 
between psychiatric co morbidity and negative behavioural factors like poor 
adherence and history of defaulting and factors like support systems, functional 
level of patients. P value was taken to be significant if it was <0.05. 
 
  
 
 
 
OBSERVATION AND RESULTS 
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  RESULTS: 
 A total of 114 patients were approached for the study. Of these, 2 
patients did not consent to participate in the study and another 3 patients were 
acutely ill, so were not included in the study. The remaining 109 patients 
consented to participate in the study. Informed consent was obtained from all 
these participants. 
 Of these 109 patients, 52.3% (n = 57) were males, 45% (n = 49) were 
females, and remaining 2.8% (n = 3) were transgender. 
 About 70.6% belonged to the age group 18-44 years, 26.6% to the 45-
64 years group, and 2.8% to the 65 or more year’s group.  
 Majority (87.2%) belonged to Hindu religion, about 3.7% were 
Muslims, and 9.2% were Christians. 
 About 14.7% were illiterate, 54.1% had primary school level 
education, 17.4% had secondary school level education, 11% had graduate 
level education, and 2.8% had post graduate level education. 
 Majorities (46.8%) were unskilled worker, 17.4% were unemployed, 
13.8% were semi-skilled workers, and 19.3% were skilled workers and 
professions were 2.8%. Nine (18.36%) of the forty-nine females were 
unemployed, while 8 (14.03%) of the 57 males were unemployed, and two of 
the three transgender were unemployed.  
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 Majority (46.8%) were from upper lower socio-economic status, 
12.8% from lower middle, and 33.9% from lower socio-economic status, and 
6.4% were from upper middle socio-economic status. No one was from upper 
socio-economic status. 
 About 61.5% were married and living with spouse, 4.6% were 
separated, 16.5% were widowed, and 17.4% were single. About 55% of spouse 
HIV status were positive, 27.5% spouse HIV status were negative and 17.4% 
of spouse HIV status were not known. Majority were from nuclear families 
(54.1%), about 42.2% from joint families, and 3.7% from broken families. 
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TABLE-1: SOCIO-DEMOGRAPHIC PROFILE OF THE STUDY 
POPULATION 
  
S. 
No. Socio-demographic variable n 
Percentage 
(%) 
 Age 
18-44 77 70.6 
45-64 29 26.6 
65 or more 3 2.8 
2 Sex 
Male 57 52.3 
Female 49 45 
Transgender 3 2.8 
3 Religion 
Hindu 95 87.2 
Muslim 4 3.7 
Christian 10 9.2 
4 Education 
Illiterate 16 14.7 
Primary school 59 54.1 
Secondary 19 17.4 
Graduate 12 11.0 
Post Graduate 3 2.8 
5 Occupation 
Unemployed 19 17.4 
Unskilled worker 51 46.8 
Semi-skilled 
worker 15 13.8 
Skilled worker 21 19.3 
Profession 3 2.8 
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S. 
No. Socio-demographic variable n 
Percentage 
(%) 
7 Socio-economic 
status 
Upper 0 0 
Upper middle 7 6.4 
Lower middle 14 12.8 
Upper lower 51 46.8 
Lower 37 33.9 
8 Marital status 
Married 67 61.5 
Single 19 17.4 
Widowed 18 16.5 
Separated 5 4.6 
9 Spouse HIV 
status 
Positive  60 55 
Negative 30 27.5 
Not known 19 17.4 
10 Type of family 
Nuclear 59 54.1 
Joint 46 42.2 
Broken 4 3.7 
 49 (45%)
Fig
19(17.4%)
Fig-2: Education wise distribution of study 
46 
 
57(52.3%)
3(2.8%)
-1: Gender  wise distribution of 
study population
16(14.7%)
59(54.1%)
12(11%)
3(2.8%)
population
 
 
Male
Female
Illiterate
primary
Secondary
Graduate
Postgraduate
  
 
 
 
 
0
10
20
30
40
50
60
7(6.4%)
Fig-
0
10
20
30
40
50
60
19(17.4%)
Fig-4: Occupation of study population
47 
14(12.8%)
51(46.8%)
37(33.9%)
3: Socioeconomic status of study 
population
51(46.8%)
15(13.8%)
21(19.3%)
3(2.8%)
 
 
Socioeconomic status
Occupation
  
 
 
 
 
46(42.2%)
Fig-5: Various Family Type of study 
0
10
20
30
40
50
60
Positive
60(55%)
Fig
48 
59(54.1%)
4(3.7%)
population
Negative Not Known
30(27.5%)
19(17.4%)
-6: Spouse HIV Status of study 
population
 
 
Nuclear
Joint
Broken
Spouse HIV Status
49 
 
 HIV/AIDS DISEASE RELATED FACTORS  
 Data regarding various HIV/AIDS disease related factors – were 
analysed. About mode of HIV transmission, 67% had sexual mode 
transmission, through blood transfusion were 7.3%, and vertical transmission 
were 4.6%, through injection drug use 1.8%, while the remaining (19.3%) were 
not known/not disclosed about their mode of HIV transmission.  
 About HIV stages, about 85% had stage I HIV, 8.3%% had stage II 
HIV, 7.3% had stage III HIV, and 6.4% had stage IV HIV. Regarding CD4 
count, 52.3% had CD4 count of  more than 500, 17.4% had between 350-500 
and 16.5% had between 200-350, while remaining 13.8% had CD4 count of 
less than 200. In treatment modality, all 109 patients were on ART therapy and 
nobody was on pre-ART therapy. TB co-infection was present in about 9.2% 
(n=10). The rest 90.8% did not have TB co-infection. 
 About ART treatment  regimen  most of  patients 62.4% (n=68) were 
on Tenofavir/Lamivudine/Efavirenz regimen. About 27.5% (n=30) were on 
Zidovudine/Lamivudine/Nevirapine regimen and 6.4% (n=7) were on 
Tenofavir/atazanavir/Ritonavir and each 0.9% (n=1) was on 
Abacavir/Lamivudine/Efavirenz, Tenofavir/Lamivudine/Nevirapine and 
Zidovudine/Lamivudine/Efavirenz.   
 Data regarding duration HIV/AIDS illness – were analysed.  About 
33% (n=36) were on between 5-10 years, 25.7% (n=28) were on between 1-5 
50 
 
years, 24.8% were on more than 10 years, and the remaining 16.5% were on 
less than 1 year. 
 
TABLE-2: HIV RELATED FACTORS IN THE STUDY POPULATION 
S. 
No. HIV related factors N 
Percentage 
(%) 
1 Mode of Transmission 
Sexual 73 67 
Injection drug 
use 
2 1.8 
Blood 
transfusion 8 7.3 
Vertical 
transmission 5 4.6 
Not known/Not 
disclosed 21 19.3 
2 HIV stage 
1 85 78 
2 9 8.3 
3 8 7.3 
4 7 6.4 
3 CD4 count 
>500 57 52.3 
350-500 19 17.4 
200-350 18 16.5 
<200 15 13.8 
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4 Treatment Modality 
Pre ART - - 
ART 109 100 
5 
 
 
 
 
Treatment Regimen 
1) tenofavir + 
lamivudine + 
efavirenz      
68 62.4 
2) abacavir+ 
lamivudine + 
efavirenz 
1 0.9 
3) Zidovudine 
+lamivudine + 
Nevirapine   
30 27.5 
4)Tenofavir + 
lamivudine + 
nevirapine    
1 0.9 
5) tenofavir + 
atazanavir + 
ritonavir  
7 6.4 
 
6)zidovudine  + 
lamivudine + 
efavirenz 
1 0.9 
7) Others 1 0.9 
6 Duration of illness 
<1 year 18 16.5 
1-5 years 28 25.7 
5-10 Years 36 33 
>10 years 27 24.8 
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   MEDICAL CO-MORBIDITY IN THE STUDY POPULATION
  Analysis of data regarding the presence of medical co
showed that, about 20.8% (n=22) had at least one medical
most common medical co
present in 9.2% (n =
 The next common co
was present in 3.7% (n =
systemic hypertension was present in 3
Anemia, Asthma, Acid peptic disease, mouth cancer 
present in 1 person each.
 Some patients actually had more than one medical co
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 10) people. 
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 4) people. Both Type 2 Diabetes Mellitus and 
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 co-morbidity. The 
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                  Table-3:
s.no Comorbidity
1 
2 
3 DM+SHT
4 
5 Jaundice
6 Asthma
7 Anemia
8 Cancer
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 Medical co-morbidities in the study population
 Frequency Percentage
DM 10 
SHT 4 
 
3 
APD 1 
 
1 
 
1 
 
1 
 
1 
22(20.2%)
-Co morbidity of study 
population
 
 
9.2 
3.7 
2.8 
0.9 
0.9 
0.9 
0.9 
0.9 
 
Present
Absent
  
  OPPORTUNISTIC INFECTION IN THE STUDY POPULATION 
 Analysis of data regarding the presence of opportunistic infection 
showed that, about 19.3% (n=2
most common opportunistic infection was Tuberculosis (both pulmonary and 
extra-pulmonary). It was present in 10
 The next common opportunistic infection was oral candidiasis, which 
was present in 6 (5.5%)
(2.8) people.  
 Seborrhic dermatitis and Angular stomatitis  
each, and 88 people were not having any opportunistic infection.
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3
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           Table-4: Opportunistic infection in the study population  
 
s.no 
Oppurtunistic 
Infection 
Frequency Percentage 
1 TB 10 9.2 
2 Candidiasis 6 5.5 
3 Herpes 3 2.8 
4 
Sebborhic 
Dermatitis 
1 0.9 
5 Angular Stomatitis 1 0.9 
6 No 88 80.7 
 
 88(80.8%)
Fig-12: Opportunistic Infection of study 
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PREVALENCE OF PSYCHIATRIC ILLNESSES IN THE STUDY 
POPULATION  
 Of the 109 people who participated in the study, 49 people (44.95%) 
had at least one psychiatric illness, including substance use disorders.  
Depressive disorder was present in 23 (21.1%) people. Among these, 
majority (47.8%, n=11) had moderate depressive disorder. Ten (43.4%) had 
mild depressive disorder, and 2 (8.7%) had severe depressive disorder as 
measured by Hamilton depression rating scale. 
Adjustment disorder was present in 9 (23.5%) patients. Eight (88.9%) had 
adjustment disorder with depressive symptoms and one (11.1) had adjustment 
disorder with anxiety symptoms. 
 Anxiety disorders were present in 2 (1.8%) patients. One had generalised 
anxiety disorder, while other had given a diagnosis of unspecified anxiety 
disorder as criteria, mostly duration criterion, were not fulfilled for other 
anxiety disorders. Among these, about 50 % had mild anxiety and 50% had 
moderate anxiety as measured by Hamilton anxiety rating scale. 
Regarding substance use, alcohol use and smoking were the disorders 
observed in the study population. Alcohol dependence syndrome was present 
in 10 (9.2%) people. Nicotine dependence syndrome (smoking) was present in 
2 (1.8%) people. 
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Regarding severity of alcohol dependence, majority (50%) fell in the risk 
zone 4 on AUDIT scores. About 10% fell in risk zone 1, 20% in risk zone 2, 
and 20% in risk zone 3. 
Regarding severity of nicotine dependence, one (50%) had medium 
dependence, while another one (50%) had high dependence, based on 
Fagerstrom test for nicotine dependence. 
Psychosis were present 2.8% (n = 3) of study population. 
Data regarding past history of psychiatric illness were analysed. One had 
past history of alcohol dependence syndrome, history of dependence in past, 
but was now abstinent for at least 12 months. About 1.8% (n=2) had a past 
history depression. No other psychiatric illness was present in the past in the 
study population. 
Regarding family history of psychiatric illness, about 18.3% (n=20) had a 
family history of psychiatric illness – alcohol dependence were present in 11 
patients family persons, family history of depression were present in 4 person, 
Bipolar affective disorder was present in one person, family history of 
psychosis were present in three persons and one had family history of 
obsessive-compulsive disorder,   No other psychiatric illness was present in the 
families of the study population. 
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TABLE-5: PREVALENCE OF PSYCHIATRIC ILLNESSES IN THE 
STUDY POPULATION 
  
S. 
No. Psychiatric illness n Percentage (%) 
1 Depressive disorder 
Mild 10 43.4% of depression 
Moderate 11 47.8% of depression 
Severe 2 8.7% of depression 
Total 23 21.1% of total patients 
2 Adjustment disorder 
With 
depressive 
symptoms 
8 88.9% of adjustment disorder 
With anxiety 
symptoms 1 
11.1% of adjustment 
disorder 
Total 9 8.3% of total patients 
3 Anxiety disorder 
        Mild          1          50% of anxiety 
      Moderate          1          50% of anxiety 
        Severe          0           0% of anxiety 
         Total          2         1.8% of total population 
4 Alcohol dependence 
syndrome 
Risk zone I 1 10% of alcohol dependence 
Risk zone II 2 20% of alcohol dependence 
Risk zone III 2 20% of alcohol dependence 
Risk zone 
IV 5 
50% of alcohol 
dependence 
Total 10 9.2% of total patients 
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                             Table-6: Family history of Psychiatric illness 
 
Family history of Psychiatric 
illness 
Frequency Percentage 
Present 20 18.3 
Absent 89 81.7 
 
             
 
 
5 
Nicotine 
dependence 
syndrome 
Very low 0 0% of NDS 
Low 0 0 of NDS 
Medium 1 50 of NDS 
High 1 50 of NDS 
Very high  0 of NDS 
Total 2 1.8% of total patients 
6 Psychosis 3 2.8% of total patients 
7 Past history of psychiatric illness 3 2.75% of total patients 
8 Family history of psychiatric illness 20 18.3% of total patients 
 
   
 Table
 
Past History of Psychiatric 
illness
Present
Absent
 
                    Table-8: 
Psychiatric illness
No 
Yes 
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in the study population
Typeof Psychiatric illness
Moderate Severe
11
2
16: Severity of Depression in the 
study population
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ASSOCIATION BETWEEN SOCIO-DEMOGRAPHIC FACTORS AND 
PSYCHIATRIC ILLNESS IN HIV/AIDS  
  Various socio-demographic data collected during the study were 
analysed for their relationship with psychiatric illnesses in HIV/AIDS. Chi 
squared and Fisher's exact probability were used for this analysis. 
 In the analyses, psychiatric illness in HIV/AIDS population, it was 
observed that male sex had a statistically significant association with presence 
of psychiatric illness. Chi square test was used and the value was 8.028, 
p=0.018. 
Table-9: Association between sex and psychiatric illnesses in the  
study population 
Gender 
Psychiatric illnesses  
Chi square P value 
Present Absent 
Male 27 30         8.028 0.018 
Female  33 16   
Transgender 0 3   
  
 Another analysis to observe the relationship between marietal status 
and presence of psychiatric illnesses. Marital status (single) was found to have a 
statistically significant association with presence of psychiatric illnesses (Chi 
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squared = 15.08, p = 0.002). All other socio-demographic variables - age group, 
religion, education, occupation, and socio-economic status did not have 
statistically significant association with presence of psychiatric illnesses.  
Table-10:Association between marital status and presence of psychiatric 
illness in the study population: 
Marietal Status 
Psychiatric illness  
Chi square P value 
Present Absent 
Married 42 25   
Single 4 15 15.08 0.002 
Widowed 13 5   
Seperated 1 4   
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TABLE-11:SOCIO-DEMOGRAPHIC FACTORS AND PRESENCE OF 
PSYCHIATRIC ILLNESSES 
 
S. 
No. 
Socio-demographic 
variable 
Psychiatric illnesses  
Chi square = 
p value 
Absent Present 
1 
Age 
(years) 
<18 1 0 
3.84 
 
18-44 39 37 0.279 
45-64 17 12  
65 or more 3 0  
2 Sex 
Male 27 30 
8.02 
 
 
0.018 
Female 33 16 
Transgender 0 3 
3 Religion 
Hindu 55 40 
5.312 
 
0.07 Muslim 0 4 
Christian 5 5 
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4 
Educa
tion 
Illiterate 9 7 
1.02 
 
 
 
            
        0.906 
Primary 
school 
31 28 
Seconda
ry 
10 9 
Graduate 8 4 
Post 
Graduate 
2 1 
5 
Occu
pation 
Unempl
oyed 
9 10 
4.38 
 
 
 
 
 
 
0.35 
Unskille
d worker 
33 18 
Semi-
skilled 
worker 
6 9 
Skilled 
worker 
10 11 
Professi
on 
2 1 
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SOCIO-DEMOGRAPHIC FACTORS AND PRESENCE OF 
PSYCHIATRIC ILLNESSES 
S. 
N
o. 
Socio-
demographic 
variable 
Psychiatric illnesses  
Chi square value 
p value 
Absent Present 
6 
Socio 
econo
mic 
status 
Upper 
middle 
4 3 
0.943 
 
            
        
0.815 
Lower 
middle 
8 6 
Upper 
lower 
30 21 
Lower 18 19 
7 
Marit
al 
status 
Married 42 25 
15.08 
 
            
          0.002 
Single 4 15 
Widowed 13 5 
Separated 1 4 
8 
Type 
of 
famil
y 
Nuclear 35 24 
 
0.95 
 
 
          0.622 
Joint 23 23 
Broken 2 2 
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HIV/AIDS DISEASE RELATED FACTORS AND PRESENCE OF   
PSYCHIATRIC ILLNESS 
HIV/AIDS disease related factors – HIV stages, CD4 count, duration of 
illness, presence of HIV-opportunistic infection, adherence and drug regimen – 
were analysed for association with presence of psychiatric illnesses. 
Of these, HIV stage (stage 4) was statistically significantly associated 
with presence of psychiatric illnesses (chi squared = 23.2, p = <0.001). 
Association between CD4 count (less than 200) and presence of psychiatric 
illness was statistically significant (chi squared = 13.48, p = 0.004). Duration 
of treatment (less than one year of treatment) was significantly associated with 
presence of psychiatric illnesses (chi squared = 25.98, p = <0.001), and person 
had poor drug adherence was statistically significantly associated with 
presence of psychiatric illnesses (chi squared = 11.45, p = 0.003).  All other 
factors – opportunistic infection, and medical co- morbidity – were not 
statistically associated with presence of psychiatric illnesses. 
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Table-12: Association between stages of HIV and presence of psychiatric 
illness – statistically significant 
Stages of 
HIV 
Psychiatric illness  
Chi 
square 
P value 
Present Absent   
1 28 57   
2 7 2   
3  7 1   
4 7 0 23.2 <0.001 
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Table-13: Association between stages CD4 Count and presence of psychiatric 
illness statistically significant 
CD4 
Count 
Psychiatric illness  
Chi 
square 
P value 
Present Absent   
>500 20 37   
350-500 7 12   
200-350 9 9   
<200 13 2 13.48 0.004 
72 
 
 
 
 
 
Table-14: Association between Duration of illness and presence of psychiatric 
illness statistically significant 
Duration 
of  illness  
Psychiatric illness  
Chi 
square 
P value 
Present Absent   
<1 year 17 1 25.98 <0.001 
1-5 years 9 19   
5-10 years 9 27   
>10 years 14 13   
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Table-15: Association between Drug adherence and presence of psychiatric 
illness statistically significant 
Drug 
adherence 
Psychiatric illness  
Chi 
square 
P value 
Present Absent   
High 21 42   
Medium 18 16   
Low 10 2 11.45 0.003 
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TABLE-16: HIV/AIDS DISEASE RELATED FACTORS AND PRESENCE 
OF PSYCHIATRIC ILLNESSES 
S. 
N
o. 
variable 
Psychiatric illnesses  
Chi square 
value 
p value 
Absent Present 
1 
Spouse 
HIV 
status 
Positive 37 23 
0.024 
 
           0.87 
Negative 19 11 
2 
Family 
history of 
Psychiatr
ic illness 
Yes 6 14 
            6.20 
 
 
         0.013 No 54 35 
3 
Past 
history of 
Psychiatr
ic illness 
Yes 1 2 
0.588 
 
 
         0.443 No 59 47 
4 
HIV 
Stage 
1 57 28 
 
 
 
23.2 
 
 
 
          <0.001 
2 2 7 
3 1 7 
4 0 7 
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5 CD4 count 
>500 37 20 
 
13.48 
 
 
0.004 
350-500 12 7 
200-350 9 9 
<200 2 13 
6 
Duration 
of illness 
<1 year 1 17 
                25.98 
 
 
<0.001 
1-5 year 19 9 
5-10year 27 9 
>10 year 13 14 
7 Adherance 
High 42 21 
 
11.45 
 
 
0.003 
Medium 16 18 
Low 2 10 
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RELATIONSHIP BETWEEN HIV OPPORTUNISTIC INFECTION 
AND PRESENCE OF PSYCHIATRIC ILLNESS 
 Presence of HIV Opportunistic infection was analysed to find if any 
statistically significant association exists with presence of psychiatric illness, 
No statistical significance was observed. 
Table-17: Association between presence of HIV opportunistic infection and 
presence of psychiatric illness – not significant 
HIV 
opportunistic
-infection 
Psychiatric illness  
Chi square 
value 
P value 
Present Absent 
1.33 0.51 
TB 9 1 
Candidiasis 4 2 
Others 4 1 
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RELATIONSHIP BETWEEN TYPE OF ANTI-RETROVIRAL 
THERAPY REGIMEN AND PRESENCE OF PSYCHIATRIC ILLNESS 
 Most commonly used anti-retroviral therapy regimens are three types 
– Tenofavir + Lamivudine + Efavirenz, Zidovudine + Lamivudine + 
Nevirapine, Tenofavir + Atazanavir + Ritonavir. Analyses were done to find if 
any statistically significant relationship exists between the type of anti-
retroviral therapy regimen and presence of psychiatric illness, and statistical 
significance was observed in Tenofavir + Lamivudine + Efavirenz regimen. 
Table-18: Association between type of ART regimen and presence of 
psychiatric illness – significant 
ART 
regimen 
Psychiatric illness  
Chi 
square 
P value 
Present Absent   
Tenofavir + 
Lamivudine 
+ Efavirenz 
34 34 14.29 0.0007 
Zidovudine 
+ 
Lamivudine 
+ 
Nevirapine 
6 24   
others 9 2   
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RELATIONSHIP BETWEEN PRESENCE OF MEDICAL CO-
MORBIDITIES AND PSYCHIATRIC ILLNESS 
 We analysed the association between the presence of other medical 
co-morbidities and the presence of psychiatric illness in the study population. 
We did not find any statistical significance in the analyses. 
 
Table-19: Association between presence of  medical co-morbidities and 
presence of psychiatric illnesses - not significant. 
Presence of 
medical co-
morbidities 
Psychiatric illnesses  Chi square P value 
Present Absent 
0.53 0.91 
DM 5 5 
SHT 2 2 
DM + SHT 1 0 
Others 3 2 
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FAMILY/PAST HISTORY OF PSYCHIATRIC ILLNESS AND 
CURRENT PRESENCE OF PSYCHIATRIC ILLNESS IN THE STUDY 
POPULATION 
Data regarding presence of family history of psychiatric illnesses in the 
study population was analysed for association with current presence of 
psychiatric illness. Of the 109 participants, 20 had a family history of 
psychiatric illness. Family history of psychiatric illness was significantly 
associated with current presence of psychiatric illness. (chi square=6.20, 
p=0.013) 
 No statistically significant relationship was observed in analysis for 
association between past history of psychiatric illness and current presence of 
psychiatric illness. (chi square=0.588, p=0.443) 
Table-20: Association between presence of family history of psychiatric illness 
and current presence of psychiatric illness - significant 
Family 
H/O 
psychiatric 
illnesses 
Current psychiatric illness  Chi square P value 
 Present Absent   
Present 14 6 6.20 0.013 
Absent 35 54   
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Table-21: Association between presence of past history of psychiatric illness 
and current presence of psychiatric illness– not significant 
Past H/O 
psychiatric 
illnesses 
Current psychiatric illness  Chi square P value 
 Present Absent   
Present 2 1 0.588 0.443 
Absent 47 59   
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ASSOCIATION BETWEEN PSYCHIATRIC ILLNESS AND SUPPORT 
SYSTEM IN HIV/AIDS DISEASE  
 In the analysis of support system and psychiatric illness, patients with low 
support system had statistical significance with presence of psychiatric illness. 
(chi square = 10.63; P = 0.005). Majority of the patients had high support system 
and had lower prevalence of psychiatric illness.  
 
Table-22:Association between psychiatric illness and support system in 
HIV/AIDS disease 
 
  
 
Psychiatric 
illness 
Multidimentional scale of 
perceived social support 
Chi 
Square 
value 
P value 
Low medium high 
Absent 3 13 44 
10.63 0.005 
Present 10 17 22 
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ASSOCIATION BETWEEN PSYCHIATRIC ILLNESS AND 
FUNCTIONAL ABILITY OF PATIENTS WITH HIV/AIDS DISEASE 
 In the analysis of functional ability using Karnofsky’s performance 
scale, patients unable to care for self and requires equivalent of institutional or 
hospital care had statistically significant association with presence of psychiatric 
illness. (chi square = 22.6; P = <0.001).  
 
Table-23: Association between psychiatric illness and functional ability of 
patients with HIV/AIDS disease 
Psychiatric illness 
Karnofsky’s performance scale 
Chi 
Square 
value 
P value 
A B C 
Absent 56 4 0 
22.6 <0.001 
Present 27 15 7 
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ASSOCIATION BETWEEN PSYCHIATRIC ILLNESS AND 
COGNITIVE FUNCTIONING IN HIV/AIDS  
 In the analysis of cognitive functioning and presence of psychiatric 
illnesses, no statistically significant association was observed. (Chi square-
1.17; P-0.278). 
 
Table-24: Association between psychiatric illness and cognitive 
functioning in HIV/AIDS disease 
Psychiatric illness 
Montreal cognitive assessment 
scale 
Chi 
square 
test 
P value 
Score ≥ 26 Score < 26 
Absent 48 12 
1.17 0.278 
Present 43 6 
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ASSOCIATION BETWEEN PSYCHIATRIC ILLNESS AND TREATMENT 
ADHERENCE IN HIV/AIDS DISEASE 
 In the analysis of treatment adherence using Morisky’s medication 
adherence scale – 4,  presence of psychiatric illnesses  were associated with low 
treatment adherence in HIV/AIDS, and  it is statistically significant (chi sguare-
11.45;p-0.003) 
 
Table-25:Association between psychiatric illness and treatment adherence in 
HIV/AIDS disease 
Psychiatric illness 
Morisky medication  
adherence scale 4 
Chi 
square 
test 
P value 
High Medium Low 
Absent 42 16 2 
11.45 0.003 
Present 21 18 10 
 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
 The total participants in our study were 109. Of these 57 (52.3%) were 
males, and 49 (45%) were females. Gender ratio varies in the previous studies; 
some have more male patients than females, while others have more female 
than male patients. About 70.6% were between 18-44 years, 26.6% were 
between 45-64 years, and 2.8% were above 65 years of age. About 87.2% 
belonged to Hindu religion, 3.7% to Muslim, and 9.2% to Christianity. This is 
consistent with the proportions observed in the general population. About 
54.1% had had primary school level education, 17.4% had secondary school 
level education, 11% had graduate level education, 2.8% had post graduate 
level education, and 14.7% had had no formal education. About 17.4% were 
unemployed, 46.8% were unskilled workers, 13.8% were semi-skilled workers, 
19.3% were skilled workers and 2.8% were profession. This is consistent with 
the findings by past study – Naresh Nebhinani et al (2010). Ten (20.40%) of 
the forty nine females were unemployed, while 9 (15.78%) of the 57 males 
were unemployed in our study. Most of the study populations (46.8%) were 
from upper lower socio-economic status.  About 33.9% from lower socio-
economic status, 12.8% from lower middle socio-economic status, and 6.45% 
from upper middle socio – economic status. The hospital where our study was 
done is a urban tertiary care institution that is government run. About 61.5% 
were living with spouse, 4% were separated, 16.5% were widowed, and 17.4% 
were single. This finding is similar with the past study – Naresh Nebhinani et 
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al (2010). Majority were from nuclear families (54.1%), about 42.2% from 
joint families, and 3.7% from broken families. This only reflects the trend in 
the general population – majorities are from nuclear families. 
About 55% of the patients had a spouse HIV status positive. About 27.5% 
had spouse HIV status negative and about 17.4% were not known about their 
spouse HIV status. Duration of illness varied widely – 16.5% were less than 
one year duration of illness, 25.7% were between 1-5 years, 33% were between 
5-10 years, and 24.3% were duration of HIV illness more than 10 years.  
HIV/AIDS services have improved much in the recent years with better 
reporting (WHO, Global HIV/AIDS report 2016), which may be one of the 
reasons for this observation. About mode of transmission, 67% had sexual 
mode of transmission, 19.3% were not disclosed or not known about mode of 
transmission, 7.3% had blood transfusion mode of transmission, 4.6% had 
vertical mode of transmission and 1.8% were injection drug use as mode of 
transmission. This is consistent with the findings by  past study-David J 
Dausey, et al (2003).  
About 20.18% (n=22) had medical co-morbidities, of which Type 2 
Diabetes Mellitus was the commonest, being present in 10 people (9.2%). This 
is comparable to the finding by Karla et al (2011), who observed that the 
prevalence of Diabetes in HIV patients was 5.7%. 
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About 45% (n=49) of the study population had at least one psychiatric 
illness. This is comparable to the findings of previous studies - Naresh 
Nebhini– 45%, D.M.Israelski, 2007 – 38%, J.A.Ciesla, 2001 – 42%. 
Depressive disorder was the most common psychiatric morbidity, present in 
about 21.1% (n=23) of the patients. Among these, 43.4% had mild, 47.8% had 
moderate, and 8.7% had severe depressive disorders. Others in the past similar 
prevalence rates – Naresh Nebhini , 2010 – 19%, J.Hampton Atkinson, 1988- 
17%, and Myer et al,2008 – 14%. Adjustment disorder was the next common 
morbidity, which was present in about 8.3% (n=9), which is similar to previous 
study done in india by Naresh Nebhini,2010– 7% 
 Alcohol dependence syndrome was the next common morbidity, 
which was present in about 9.2% (n=10) of the patients. Majority (50%) of the 
patients fell in the risk zone 4 based on AUDIT scores. The prevalence of 
alcohol dependence syndrome as observed in our study is similar to previous 
study-Myer et al,2008-7%, and much lower than the prevalence reported in the 
previous study.- Atkinson et al,1988-22% 
About 1.8% (n=2) had nicotine dependence syndrome. This is much 
lower than the prevalence in the general population which is 24.3% in males in 
India (WHO report on the global tobacco epidemic, 2015). No other substance 
use disorders were reported in our study. 
Anxiety disorders were the next most common morbidity – present in 
about 1.8% (n=2) patients. Among these, one patient had mild anxiety, and one 
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patient had moderate anxiety on Hamilton Anxiety Rating Scale scores. The 
prevalence of anxiety disorders in our study is much lower than the prevalence 
reported in the previous studies – Mukesh Shula et al,2016;  Sreelekshmi 
R,2015, who observed a prevalence of 15-40 % for any anxiety disorder.  
About 2.8% (n=3) of the total study population had psychosis. This 
finding was higher than the prevalence reported in previous study- Naresh 
Nebhini , 2010,who observed a prevalence of less than one percent. 
About 2.8% (n=3) of the patients had a past history psychiatric illness, 
Among these three one had past history alcohol dependence, and was currently 
abstinent for at least 12 months, other two had past history of depression. The 
reasons for stopping alcohol use in this patient  – worry regarding deteriorating 
health, poor income due to loss of job. 
About 18.3% (n=20) had a family history of psychiatric illness – alcohol 
dependence-11, Depression-4, psychosis-3, Bipolar affective disorder-1, 
obsessive compulsive disorder-1. No other psychiatric illness was reported. 
 Among various socio-demographic factors, male gender was 
significantly associated with presence of psychiatric illnesses (chi square = 
8.02, p=0.018). This is in variance with most studies in the past, which have 
found either that female or male gender was more associated with psychiatric 
illness in HIV/AIDS, or that there was no significant difference. 
Marital status, single - as opposed to married, widowed, and separated – 
was significantly associated with presence of psychiatric illnesses  (Chi 
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squared = 15.08, p = 0.002). This is in variance with the findings of Naresh 
Nebhini (2010), who observed that married was more associated with 
psychiatric illness. All other variables – age group, religion, education, 
occupation, family income, socio-economic status – did not reach statistical 
significance. Past studies show only equivocal results for almost all socio-
demographic variables. 
 Among the HIV/AIDS disease related factors, family history of 
psychiatry illness was significantly associated with presence of psychiatric 
illnesses, (chi squared = 6.20, p = 0.013). Stages of HIV (stage 4) were 
significantly associated with presence of psychiatric illnesses, (chi 
square=23.2; p= <0.001). CD4 count (less than 2000 was significantly 
associated with presence of psychiatric illnesses, (chi square=13.48; p=0.004). 
This finding is similar to G.Lykestos et al:1993, and ART drug adherence (low 
adherence) was significantly associated with presence of psychiatric illnesses 
(chi square=11.45;p=.003), This is similar to Yun et al,2005 and Peter s et 
al,2001 . Shorter duration of illness (Less than one year) has been found to be 
associated with presence of psychiatric illnesses in our study (chi 
square=25.98;p= <0.001). This finding is similar to previous studies- Davis et 
al 1995; Holt et al 1998. All the other factors – spouse HIV status, past history 
of psychiatry illness, presence of HIV opportunistic infection – were not 
statistically associated with presence of psychiatric illnesses. 
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We had find significance in the association between type of ART regimen 
(Tenofavir + Lamivudine + Efavirenz) and presence of psychiatric illness,(chi 
square=14.34;p=0.0007). This is in similar with Fumas et al,2005. 
 We did not find statistical significance in the analysis of association 
between presence of medical co-morbidities and presence of psychiatric 
illnesses. This is variance with the findings by Perry et al (1984), who found 
that medical co morbidities in general increase the risk of psychiatric illness. In 
our study, diabetes was the most common medical co morbidity, accounting 
for about 70% of the total medial co-morbidities. 
        We did find statistical significance in the analysis of association between 
presence of support system and presence of psychiatric illnesses. Persons had 
low support system were significantly associated with psychiatric illness,(chi 
square=10.63;p=0.005).This finding is similar with the findings by Catalan et 
al, 1995; Katz et al,1996. 
     We also did find significant association between functional ability and 
presence of psychiatric illness. Person had low functional ability were 
significantly associated with psychiatric illness. This is consistent with the 
findings of Lykestos (2010) and Dilley,J.W (1999). 
      We did not find statistical significance in the analysis of association 
between presence of cognitive functioning and presence of psychiatric 
illnesses. This is variance with the findings by Wolcott,et al (1989);Price,et 
al,1988;Navia, et al,1986. 
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 Summarising, the prevalence of psychiatric illnesses in the study 
population was 45%. Depressive disorder was the commonest morbidity 
(21.1%), followed by alcohol dependence syndrome (9.2%), Adjustment 
disorder (8.3%), Psychosis (2.8%), and nicotine dependence syndrome (1.8%), 
and anxiety disorders (1.8%).  
Statistically significant associations were observed between the following 
variables in the study population: 
• Male gender and presence of psychiatric illnesses. 
• Single and presence of psychiatric illnesses. 
• Family history of psychiatry illness and presence of psychiatric 
illnesses. 
• HIV stage 4 and presence of psychiatric illnesses. 
• CD4 Count less than 200 and presence of psychiatric illnesses. 
• Duration of HIV/AIDS less than one year and presence of psychiatric 
illnesses. 
• Poor ART drug adherence and presence of psychiatric illnesses. 
• Low support system and presence of psychiatric illnesses 
• Low functional ability and presence of psychiatric illnesses. 
 
                                                  
 
  
 
 
 
CONCLUSION 
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CONCLUSION 
 In our study, high prevalence (45%) of psychiatric illnesses in patients 
with HIV/AIDS has been observed. Psychiatric Comorbidity is associated with 
poor treatment adherence in general and this is observed in our study also. 
Addressing the psychiatric illness in this population can lead to significant 
improvement in treatment adherence and it can improve the outcome of 
HIV/AIDS. 
 In our study, Depression is the most common psychiatric morbidity 
(20 %) followed by alcohol dependence and adjustment disorders and while 
organizing mental health services for the HIV positive patients this factor 
should be considered. Depression is easily identifiable and can be easily 
treated. The prevalence of depression in this population is much higher than 
that in the general population.  
Alcohol dependent individuals tend to lead a chaotic life-style that will 
interfere with their compliance to treatment. So, Alcohol use in individual with 
HIV/AIDS should be effectively identified and managed. The association of 
male gender and single status on psychiatric morbidity is probably due to 
increased prevalence of alcohol dependence in this population and this group 
may be considered as a specially vulnerable sub group among those with HIV. 
The association between low CD4 count and advanced disease and psychiatric 
illness indicates the possibility of a vicious cycle of non compliance, illness 
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progress and psychiatric morbidity which needs to be identified early for 
intervention. 
The association between certain drug regimen and psychiatric 
comorbidity needs to be analysed further. 
An effective liaison services between the physicians treating HIV/AIDS 
and psychiatric services can improve the adherence to treatment and outcome 
HIV/AIDS and thereby improve the quality of life of people with HIV/AIDS. 
 
LIMITATIONS OF THE STUDY 
Our study is a hospital based, cross sectional, observational study which 
provides data on prevalence of psychiatric comorbidity. An analytical and 
longitudinal study may be better suited for conclusion regarding factors 
associated with psychiatric comorbidity. Participant factors like recall bias may 
have interfered with certain information. And personality factors were not 
assessed in our study. 
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ANNEXURE 
  
INFORMED CONSENT FORM 
STUDY: “Psychiatric co-morbidity in people with HIV/AIDS : a cross 
sectional study”. 
STUDY CENTRE: ART Center, Govt. Kilpauk Medical College Hospital. 
PATIENT’S NAME : 
PATIENT’S AGE : 
I.P NO.   : 
Patient may check ( ) these boxes 
I confirm that I understood the purpose of the procedure for the above 
study.         ( ) 
I had the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction.    ( ) 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights 
being affected.         ( ) 
I understand that the ethical committee members  and the regulatory 
authorities will not need my permission to look at my health records, both 
in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this 
access.           ( ) 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under 
the law.          ( ) 
I agree not to restrict the use of any data or results that arise from the 
study.         ( ) 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully co-operate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.( ) 
I hereby consent to participate in this study.    ( ) 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
           ( ) 
 
 
Signature / thumb impression 
Patient’s name and address: 
 
 
Place: 
Date: 
 
 
Signature of the investigator: 
Study investigator’s name: 
Place: 
Date: 
PARTICIPANTS' INFORMATION SHEET 
 
Investigator  : Dr V.Vijayakumar 
Name of the participant :  
 
Study title: “Psychiatric Co-morbidity in people with HIV/AIDS : a 
cross sectional study”. 
 
 You are invited to take part in this research study. We have got 
approval from the IEC. You are asked to participate because you satisfy 
the eligibility criteria. 
 
What is the purpose of this research? 
 In this study, we aim to assess the prevalence of psychiatric illnesses 
in people undergoing treatment for HIV/AIDS, the association between 
psychiatric comorbidity and different sociodemographic factors (age, 
gender, education) and disease related factors (duration of illness, stages of 
HIV/AIDS,CD4 count, HIV-TB coinfection), to assess the relationship 
between psychiatric comorbidity and negative behavioural factors like 
poor adherence and history of defaulting. This will help in assessing the 
burden of psychiatric illnesses in people with HIV/AIDS and how it 
affects the outcome of HIV/AIDS, so that earlier detection and treatment 
of psychiatric illnesses may improve the outcome of HIV/AIDS.  
 
 
 
 
Benefits: 
 This study will benefit all people who are undergoing treatment for 
HIV/AIDS and help improve the drug adherence and follow up rate of 
HIV/AIDS treatment, and also reduce the incidence of death due to  
HIV/AIDS. 
Discomforts and risks: 
 No interventional procedure is done in this study. 
Confidentiality: 
 Patients who participate in the study and their details will be 
maintained confidentially and at any cost, those details will not be let out. 
 
Right to withdraw: 
Patients will not be forced to complete the study. At any cost, in such 
circumstances the treatment will not be compromised. 
 
 
 
Signature/Thumb impression of the participant: 
 
 
Signature of the investigator: 
 
Date : 
Place : 
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ெத?வIேபA என உCதி அள#'கிேறA.     
        ( ) 
இLத ஆவI என'( ம&0=வ ப?ேசாதைன ெச= ெகாள 
மMC ஆவI பBேகMக நாA DT மன=டA 
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    ( ) 
பBேகMபவ?A ைகெயாப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___________________ 
இட: ____________________________ 
ேததி: _____________________________ 
பBேகMபவ?A ெபய! மMC வIலாச:: 
 
ஆவாள?A ைகெயாப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இட _________________________ 
ேததி __________________________ 
ஆவாள?A ெபய! ____________________________ 
ஆரா2சி தகவ தா 
 கி<பா'க அர ெபா= ம&0=வமைனயI HIV/AIDS 
உளவ!கள#ட இ&'( மனேநாகைள' (றி0= ஆரா2சி 
ெசய உேளா.  நWBக இLத ஆரா2சியI பBேகMக 
நாBக வI&கிேறா. இLத ஆரா2சியI பBேகMபதா 
தBகள= ேநாயIA ஆவறி'ைகேயா அல= சிகி2ைசேயா 
பாதி'கபடா= எAபைதS ெத?வI0=' ெகாகிேறா. 
 இLத ஆரா2சியIA D
கைள அல= க&0=கைள 
ெவள#யI ேபாேதா அல= ஆரா2சியIA ேபாேதா தBகள= 
ெபயைரேயா அல= அைடயாளBகைளேயா 
ெவள#யIடமாJேடா எAபைதS ெத?வI0=' ெகாகிேறா. 
 இLத ஆரா2சியI பBேகMப= தBகQைடய 
வI&ப0திA ேப? தாA இ&'கிற=. ேமP நWBக 
எLேநரD இLத ஆரா2சியI இ&L= பIAவாBகலா 
எAபைதS ெத?வI0='ெகாகிேறா. 
 இLத சிற ப?ேசாதைனகள#A D
கைள 
ஆரா2சியIA ேபாேதா அல= ஆரா2சியIA D
வIA 
ேபாேதா தBகQ'( அறிவIேபா எAபைதS 
ெத?வI0='ேகாகிேறா.  
 
 
ஆரா2சியாள! ைகெயாப  பBேகMபாள! ைகெயாப 
ேததி: 
PROFORMA 
 Age 
 Sex 
 1) male  2)female  3)transgender 
  Education  
1)illiterate  2)primary level  3)secondary   4)graduate   
5)postgraduate 
 Socio economic status 
  1) upper   2) upper middle  3) lower middle  4) upper lower   5) 
lower 
 Religion 
  1) Hindu   2)Muslim   3) Christian   4) others 
 Occupation 
           1) Unemployed   2) Unskilled worker   3) Semi – skilled worker   
4) Skilled worker   5) Profession 
 Marital status  
         1) single   2) married   3) widowed   4)separated 
 
 Spouse HIV status 
1) Positive  2) negative 
 Family type:  1) nuclear  2) joint  3) broken 
 Family h/o psychiatric illness: 1)yes     2) no 
 
 Past h/o psychiatric illness :  1) YES   2) NO 
 Age at HIV/AIDS diagnosis: 
 Mode of transmission 
         1) sexual  2) injection drug use  3) others   4) blood transfusion  
5)vertical transmission 6) not known/not disclosed  
 HIV/AIDS  stage:  1- 2- 3- 4-  
 Treatment modality : 1) PRE ART  2) ART 
 Treatment Regimen: 1) tenofavir + lamivudine + efavirenz     2) 
abacavir+ lamivudine + efavirenz    3) Zidovudine +lamivudine + 
Nevirapine  4)Tenofavir + lamivudine + nevirapine   5) tenofavir + 
atazanavir + ritonavir 6)zidovudine  + lamivudine + efavirenz 7) Others 
 Duration of illness: 1)<1 yrs  2) 1-5 yrs  3) 5-10 yrs  4)>10 yrs 
 Co-morbid medical illness: 1)DM  2)SHT  3)DM + SHT  4) NO 5) Acid 
peptic disease  6) Jaundice  7) asthma 9) cancer 
 Opportunistic infections : 1)TB  2)candidiasis  3)Herpes  4) seborrhoric 
dermatitis  5) angular chelitis  6)no 
 Psychiatric illness 
1) no    2) Yes  :   1)depression 2)adjustment disorder  3)alcohol 
dependence syndrome  4)anxiety disorder 5)psychosis  6)nicotine 
dependence syndrome 7) ADS + NDS  
Severity of psychiatric illness:1)Mild    2)Moderate    3)Severe    
 MoCA score: 
 Treatment adherence:     1) high  2) medium  3) low  
 MSPSS score : 1) low support  2) medium 3) high 
 KPS (functional ability):  1) A 2)B 3)C . 
 
 
 
3
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Revised table (Table 1) for scales in 2012 to define socioeconomic status thus obtained is as follows.
Table: 1. Kuppuswamy’s Socioeconomic Status Scale
(A) Education Score
1 Profession or Honours 7
2 Graduate or post graduate 6
3 Intermediate or post high school diploma 5
4 High school certificate 4
5 Middle school certificate 3
6 Primary school certificate 2
7 Illiterate 1
(B) Occupation Score
1 Profession 10
2 Semi-Profession 6
3 Clerical, Shop-owner, Farmer 5
4 Skilled worker 4
5 Semi-skilled worker 3
6 Unskilled worker 2
7 Unemployed 1
(C) Monthly family income in Rs Score Modified for 1998 3 in Rs Modified for 2012 in Rs
1 ≥ 2000 12 ≥ 13500 ≥32050
2 1000-1999 10 6750 - 13499 16020 – 32049
3 750-999 6 5050 - 6749 12020 – 16019
4 500-749 4 3375 - 5049 8010 – 12019
5 300-499 3 2025 - 3374 4810 – 8009
6 101-299 2 676 - 2024 1601 – 4809
7 ≤ 100 1 ≤ 675 ≤ 1600
Total Score Socioeconomic class
26-29 Upper (I)
16-25 Upper Middle (II)
11-15 Middle/Lower middle (III)
5-10 Lower/Upper lower (IV)
<5 Lower (V)
BP Ravi Kumar., Kuppuswamy’s Socio-Economic Status Scale - a revision of economic parameter for 2012 ijrdh.com
ijrdh.com
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Name_________________________ ID# ___________________Date ______________
SCL-90
Below is a list of problems and complaints that people sometimes have. Please read each one care-
fully. After you have done so, select one of the numbered descriptors that best describes HOW 
MUCH THAT PROBLEM HAS BOTHERED OR DISTRESSED YOU DURING THE 
PAST WEEK, INCLUDING TODAY. Circle the number in the space to the right of the prob-
lem and do not skip any items. Use the following key to guide how you respond:
  Circle 0 if your answer is NOT AT ALL
  Circle 1 if A LITTLE BIT
  Circle 2 if MODERATELY
  Circle 3 if QUITE A BIT
  Circle 4 if EXTREMELY
Please read the following example before beginning:
Example: In the previous week, how much were you bothered by:
   Backaches     0 1 2 3 4
In this case, the respondent experienced backaches a little bit (1).  
Please proceed with the questionnaire.
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1. Headaches 0 1 2 3 4
2. Nervousness or shakiness inside 0 1 2 3 4
3. Unwanted thoughts, words, or ideas that won’t leave your mind 0 1 2 3 4
4. Faintness or dizziness 0 1 2 3 4
5. Loss of sexual interest or pleasure 0 1 2 3 4
6. Feeling critical of others 0 1 2 3 4
7. The idea that someone else can control your thoughts 0 1 2 3 4
8. Feeling others are to blame for most of your troubles 0 1 2 3 4
9. Trouble remembering things 0 1 2 3 4
10. Worried about sloppiness or carelessness 0 1 2 3 4
11. Feeling easily annoyed or irritated 0 1 2 3 4
12. Pains in heart or chest 0 1 2 3 4
13. Feeling afraid in open spaces or on the streets 0 1 2 3 4
14. Feeling low in energy or slowed down 0 1 2 3 4
15. Thoughts of ending your life 0 1 2 3 4
16. Hearing voices that other people do not hear 0 1 2 3 4
17. Trembling 0 1 2 3 4
18. Feeling that most people cannot be trusted 0 1 2 3 4
19. Poor appetite 0 1 2 3 4
Copyright © 2000–2009 by Dr. John M. Gottman and Dr. Julie Schwartz Gottman. 
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SCL-90 (continued)
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20. Crying easily 0 1 2 3 4
21. Feeling shy or uneasy with the opposite sex 0 1 2 3 4
22. Feeling of being trapped or caught 0 1 2 3 4
23. Suddenly scared for no reason 0 1 2 3 4
24. Temper outbursts that you could not control 0 1 2 3 4
25. Feeling afraid to go out of your house alone 0 1 2 3 4
26. Blaming yourself for things 0 1 2 3 4
27. Pains in lower back 0 1 2 3 4
28. Feeling blocked in getting things done 0 1 2 3 4
29. Feeling lonely 0 1 2 3 4
30. Feeling blue 0 1 2 3 4
31. Worrying too much about things 0 1 2 3 4
32. Feeling no interest in things 0 1 2 3 4
33. Feeling fearful 0 1 2 3 4
34. Your feelings being easily hurt 0 1 2 3 4
35. Other people being aware of your private thoughts 0 1 2 3 4
36. Feeling others do not understand you or are unsympathetic 0 1 2 3 4
37. Feeling that people are unfriendly or dislike you 0 1 2 3 4
38. Having to do things very slowly to insure correctness 0 1 2 3 4
39. Heart pounding or racing 0 1 2 3 4
40. Nausea or upset stomach 0 1 2 3 4
41. Feeling inferior to others 0 1 2 3 4
42. Soreness of your muscles 0 1 2 3 4
43. Feeling that you are watched or talked about by others 0 1 2 3 4
44. Trouble falling asleep 0 1 2 3 4
45. Having to check and double-check what you do 0 1 2 3 4
46. Difficulty making decisions 0 1 2 3 4
47. Feeling afraid to travel on buses, subways, trains 0 1 2 3 4
48. Trouble getting your breath 0 1 2 3 4
49. Hot or cold spells 0 1 2 3 4
50.
Having to avoid certain things, places, or activities because they 
frighten you 0 1 2 3 4
51. Your mind going blank 0 1 2 3 4
52. Numbness or tingling in parts of your body 0 1 2 3 4
53. A lump in your throat 0 1 2 3 4
54. Feeling hopeless about the future 0 1 2 3 4
55. Trouble concentrating 0 1 2 3 4
Copyright © 2000–2009 by Dr. John M. Gottman and Dr. Julie Schwartz Gottman. 
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SCL-90 (continued)
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56. Feeling weak in parts of your body 0 1 2 3 4
57. Feeling tense or keyed up 0 1 2 3 4
58. Heavy feelings in your arms or legs 0 1 2 3 4
59. Thoughts of death or dying 0 1 2 3 4
60. Overeating 0 1 2 3 4
61. Feeling uneasy when people are watching or talking about you 0 1 2 3 4
62. Having thoughts that are not your own 0 1 2 3 4
63. Having urges to beat, injure, or harm someone 0 1 2 3 4
64. Awakening in the early morning 0 1 2 3 4
65. Having to repeat the same actions such as touching, counting, washing 0 1 2 3 4
66. Sleep that is restless or disturbed 0 1 2 3 4
67. Having urges to break or smash things 0 1 2 3 4
68. Having ideas or beliefs that others do not share 0 1 2 3 4
69. Feeling very self-conscious with others 0 1 2 3 4
70. Feeling uneasy in crowds, such as shopping or at a movie 0 1 2 3 4
71. Feeling everything is an effort 0 1 2 3 4
72. Spells of terror or panic 0 1 2 3 4
73. Feeling uncomfortable about eating or drinking in public 0 1 2 3 4
74. Getting into frequent arguments 0 1 2 3 4
75. Feeling nervous when you are left alone 0 1 2 3 4
76. Others not giving you proper credit for your achievements 0 1 2 3 4
77. Feeling lonely even when you are with people 0 1 2 3 4
78. Feeling so restless you couldn’t sit still 0 1 2 3 4
79. Feelings of worthlessness 0 1 2 3 4
80. Feeling that familiar things are strange or unreal 0 1 2 3 4
81. Shouting or throwing things 0 1 2 3 4
82. Feeling afraid you will faint in public 0 1 2 3 4
83. Feeling that people will take advantage of you if you let them 0 1 2 3 4
84. Having thoughts about sex that bother you a lot 0 1 2 3 4
85. The idea that you should be punished for your sins 0 1 2 3 4
86. Feeling pushed to get things done 0 1 2 3 4
87. The idea that something serious is wrong with your body 0 1 2 3 4
88. Never feeling close to another person 0 1 2 3 4
89. Feelings of guilt 0 1 2 3 4
90. The idea that something is wrong with your mind 0 1 2 3 4
 
Reference: Derogatis, L.R., Lipman, R.S., & Covi, L. (1973). SCL-90: An outpatient psychiatric rating scale—Preliminary 
Report. Psychopharmacol. Bull. 9, 13–28.
HAMILTON DEPRESSION RATING SCALE (HAM-D)
(To be administered by a health care professional)
Patient Name  ________________________________________________ Today’s Date __________________
The HAM-D is designed to rate the severity of depression in patients. Although it contains 21 areas, calculate the patient’s
score on the first 17 answers.
1. DEPRESSED MOOD
(Gloomy attitude, pessimism about the future,
feeling of sadness, tendency to weep)
0 = Absent
1 = Sadness, etc.
2 = Occasional weeping
3 = Frequent weeping
4 = Extreme symptoms
2. FEELINGS OF GUILT
0 = Absent
1 = Self-reproach, feels he/she has let people
down
2 = Ideas of guilt 
3 = Present illness is a punishment; delusions 
of guilt
4 = Hallucinations of guilt 
3. SUICIDE
0 = Absent
1 = Feels life is not worth living
2 = Wishes he/she were dead 
3 = Suicidal ideas or gestures
4 = Attempts at suicide 
4. INSOMNIA - Initial
(Difficulty in falling asleep)
0 = Absent
1 = Occasional
2 = Frequent
5. INSOMNIA - Middle
(Complains of being restless and disturbed 
during the night. Waking during the night.)
0 = Absent
1 = Occasional
2 = Frequent
6. INSOMNIA - Delayed
(Waking in early hours of the morning and 
unable to fall asleep again)
0 = Absent
1 = Occasional
2 = Frequent
7. WORK AND INTERESTS
0 = No difficulty
1 = Feelings of incapacity, listlessness, indeci-
sion and vacillation
2 = Loss of interest in hobbies, decreased social
activities
3 = Productivity decreased
4 = Unable to work. Stopped working because
of present illness only. (Absence from work
after treatment or recovery may rate a lower
score).
8. RETARDATION
(Slowness of thought, speech, and activity; 
apathy; stupor.)
0 = Absent
1 = Slight retardation at interview
2 = Obvious retardation at interview
3 = Interview difficult
4 = Complete stupor
9. AGITATION
(Restlessness associated with anxiety.)
0 = Absent
1 = Occasional
2 = Frequent
10. ANXIETY - PSYCHIC
0 = No difficulty
1 = Tension and irritability
2 = Worrying about minor matters
3 = Apprehensive attitude
4 = Fears 
■
■
■
■
■
■
■
■
■
■
HAMILTON DEPRESSION RATING SCALE (HAM-D)
(To be administered by a health care professional)
11. ANXIETY - SOMATIC
Gastrointestinal, indigestion
Cardiovascular, palpitation, Headaches
Respiratory, Genito-urinary, etc.
0 = Absent
1 = Mild
2 = Moderate
3 = Severe
4 = Incapacitating
12. SOMATIC SYMPTOMS - 
GASTROINTESTINAL
(Loss of appetite , heavy feeling in abdomen;
constipation)
0 = Absent
1 = Mild
2 = Severe
13. SOMATIC SYMPTOMS - GENERAL
(Heaviness in limbs, back or head; diffuse
backache; loss of energy and fatiguability)
0 = Absent
1 = Mild
2 = Severe
14. GENITAL SYMPTOMS
(Loss of libido, menstrual disturbances)
0 = Absent
1 = Mild
2 = Severe
15. HYPOCHONDRIASIS
0 = Not present
1 = Self-absorption (bodily)
2 = Preoccupation with health
3 = Querulous attitude
4 = Hypochondriacal delusions
16. WEIGHT LOSS
0 = No weight loss
1 = Slight
2 = Obvious or severe
17. INSIGHT
(Insight must be interpreted in terms of pa-
tient’s understanding and background.)
0 = No loss
1 = Partial or doubtfull loss
2 = Loss of insight
TOTAL ITEMS 1 TO 17: _______________
0 - 7 = Normal
8 - 13 = Mild Depression
14-18 = Moderate Depression
19 - 22 = Severe Depression
> 23 = Very Severe Depression
18. DIURNAL VARIATION
(Symptoms worse in morning or evening.
Note which it is. ) 
0 = No variation
1 = Mild variation; AM (    )  PM (    )
2 = Severe variation; AM (    )  PM (    )
19. DEPERSONALIZATION AND 
DEREALIZATION
(feelings of unreality, nihilistic ideas)
0 = Absent
1 = Mild
2 = Moderate
3 = Severe
4 = Incapacitating
20. PARANOID SYMPTOMS
(Not with a depressive quality)
0 = None
1 = Suspicious
2 = Ideas of reference
3 = Delusions of reference and persecution
4 = Hallucinations, persecutory
21. OBSESSIONAL SYMPTOMS
(Obsessive thoughts and compulsions against
which the patient struggles)
0 = Absent
1 = Mild
2 = Severe
■
■
■
■
■
■
■
■
■
* Adapted from Hamilton, M. Journal of Neurology, Neurosurgery, and Psychiatry. 23:56-62, 1960.
■
■
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Below is a list of phrases that describe certain feeling that people have. Rate the patients by finding the answer which best describes the extent
to which he/she has these conditions. Select one of the five responses for each of the fourteen questions.
0 = Not present, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very severe.
Hamilton Anxiety Rating Scale (HAM-A)
         
    
    
    
    
    
    
    
    
    
    
    
    
1 Anxious mood 0 1 2 3 4
Worries, anticipation of the worst, fearful anticipation, irritability.
2 Tension 0 1 2 3 4
Feelings of tension, fatigability, startle response, moved to tears
easily, trembling, feelings of restlessness, inability to relax.
3 Fears 0 1 2 3 4
Of dark, of strangers, of being left alone, of animals, of traffic, of
crowds.
4 Insomnia 0 1 2 3 4
Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue
on waking, dreams, nightmares, night terrors.
5 Intellectual 0 1 2 3 4
Difficulty in concentration, poor memory.
6 Depressed mood 0 1 2 3 4
Loss of interest, lack of pleasure in hobbies, depression, early waking,
diurnal swing.
7 Somatic (muscular) 0 1 2 3 4
Pains and aches, twitching, stiffness, myoclonic jerks, grinding of
teeth, unsteady voice, increased muscular tone.
8 Somatic (sensory) 0 1 2 3 4
Tinnitus, blurring of vision, hot and cold flushes, feelings of weakness,
pricking sensation.
9 Cardiovascular symptoms 0 1 2 3 4
Tachycardia, palpitations, pain in chest, throbbing of vessels, fainting
feelings, missing beat.
10 Respiratory symptoms 0 1 2 3 4
Pressure or constriction in chest, choking feelings, sighing, dyspnea.
11 Gastrointestinal symptoms 0 1 2 3 4
Difficulty in swallowing, wind abdominal pain, burning sensations,
abdominal fullness, nausea, vomiting, borborygmi, looseness of
bowels, loss of weight, constipation.
12 Genitourinary symptoms 0 1 2 3 4
Frequency of micturition, urgency of micturition, amenorrhea,
menorrhagia, development of frigidity, premature ejaculation, loss of
libido, impotence.
13 Autonomic symptoms 0 1 2 3 4
Dry mouth, flushing, pallor, tendency to sweat, giddiness, tension
headache, raising of hair.
14 Behavior at interview 0 1 2 3 4
Fidgeting, restlessness or pacing, tremor of hands, furrowed brow,
strained face, sighing or rapid respiration, facial pallor, swallowing,
etc.
The Alcohol Use Disorders Identification Test: Interview Version
Read questions as written. Record answers carefully. Begin the AUDIT by saying 
“Now I am going to ask you some questions about your use of alcoholic beverages 
during this past year.” Explain what is meant by “alcoholic beverages” by using 
local examples of beer, wine, vodka, etc. Code answers in terms of “standard 
drinks”. Place the correct answer number in the box at the right.
1. How often do you have a drink containing alco-
hol?
(0) Never [Skip to Qs 9-10]
(1) Monthly or less
(2) 2 to 4 times a month
(3) 2 to 3 times a week
(4) 4 or more times a week
2. How many drinks containing alcohol do you have
on a typical day when you are drinking?
(0) 1 or 2
(1) 3 or 4
(2) 5 or 6
(3) 7, 8, or 9
(4) 10 or more
3. How often do you have six or more drinks on one
occasion?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
Skip to Questions 9 and 10 if Total Score
for Questions 2 and 3 = 0
4. How often during the last year have you found
that you were not able to stop drinking once you
had started?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
5. How often during the last year have you failed to
do what was normally expected from you
because of drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
6. How often during the last year have you needed
a first drink in the morning to get yourself going
after a heavy drinking session?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
7. How often during the last year have you had a
feeling of guilt or remorse after drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
8. How often during the last year have you been
unable to remember what happened the night
before because you had been drinking?
(0) Never
(1) Less than monthly
(2) Monthly
(3) Weekly
(4) Daily or almost daily
9. Have you or someone else been injured as a
result of your drinking?
(0) No
(2) Yes, but not in the last year
(4) Yes, during the last year
10. Has a relative or friend or a doctor or another
health worker been concerned about your drink-
ing or suggested you cut down?
(0) No
(2) Yes, but not in the last year
(4) Yes, during the last year
Record total of specific items here
If total is greater than recommended cut-off, consult User’s Manual.
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Morisky 8-Item Medication Adherence Questionnaire
Question
Patient  
Answer
(Yes/No)
Score
Y=1;  
N=0
Do you sometimes forget to take your medicine?
People sometimes miss taking their medicines for reasons other 
than forgetting. Thinking over the past 2 weeks, were there any 
days when you did not take your medicine?
Have you ever cut back or stopped taking your medicine 
without telling your doctor because you felt worse when  
you took it?
When you travel or leave home, do you sometimes forget to 
bring along your medicine?
Did you take all your medicines yesterday?
When you feel like your symptoms are under control, do you 
sometimes stop taking your medicine?
Taking medicine every day is a real inconvenience for some 
people. Do you ever feel hassled about sticking to your 
treatment plan?
How often do you have difficulty remembering to take all your 
medicine?
 __ A. Never/rarely
 __ B. Once in a while
 __ C. Sometimes
 __ D. Usually
 __ E. All the time
A = 0; 
B-E = 1
Total score
   Scores: >2 = low adherence 
1 or 2 = medium adherence 
0 = high adherence
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. 
Med Care. 1986;24:67-74.
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The Karnofsky Performance Scale Index allows patients to be classified as to their functional 
impairment. This can be used to compare effectiveness of different therapies and to assess the 
prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most 
serious illnesses.  
KARNOFSKY PERFORMANCE STATUS SCALE DEFINITIONS RATING (%) 
CRITERIA 
  100  Normal no complaints; no evidence of disease.
90 Able to carry on normal activity; minor signs or symptoms of disease. Able to carry on normal activity and to work; no special care needed. 
80 Normal activity with effort; some signs or symptoms of disease.  
70 Cares for self; unable to carry on normal activity or to do active work. 
60 Requires occasional assistance, but is able to care for most of his personal needs. 
Unable to work; able to live at home and care for 
most personal needs; varying amount of assistance 
needed. 
50 Requires considerable assistance and frequent medical care.  
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is indicated although death not imminent. 
20 Very sick; hospital admission necessary; active supportive treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly. 
0 Dead 
References: 
Crooks, V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes 
and risk in geriatric outpatients. J Gerontol. 1991; 46: M139-M144. 
de Haan R, Aaronson A, et al. Measuring quality of life in stroke. Stroke. 1993; 24:320- 327. 
Hollen PJ, Gralla RJ, et al. Measurement of quality of life in patients with lung cancer in 
multicenter trials of new therapies. Cancer. 1994; 73: 2087-2098. 
O'Toole DM, Golden AM. Evaluating cancer patients for rehabilitation potential. West J Med. 
1991; 155:384-387. 
Oxford Textbook of Palliative Medicine, Oxford University Press. 1993;109. 
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, 
and guidelines. J Clin Oncology. 1984; 2:187-193. 
Multidimensional Scale of Perceived Social Support (Zimet, Dahlem, Zimet & Farley, 1988) 
 
Instructions:  We are interested in how you feel about the following statements.  Read each statement 
carefully.   Indicate how you feel about each statement. 
 
   Circle the “1” if you Very Strongly Disagree 
   Circle the “2” if you Strongly Disagree 
   Circle the “3” if you Mildly Disagree 
   Circle the “4” if you are Neutral 
   Circle the “5” if you Mildly Agree 
   Circle the “6” if you Strongly Agree 
   Circle the “7” if you Very Strongly Agree 
 
 
 1. There is a special person who is around when I 
am in need. 
1 2 3 4 5 6 7 SO 
 2. There is a special person with whom I can share 
my joys and sorrows. 
1 2 3 4 5 6 7 SO 
 3. My family really tries to help me. 1 2 3 4 5 6 7 Fam 
 4. I get the emotional help and support I need from 
my family. 
1 2 3 4 5 6 7 Fam 
 5.  I have a special person who is a real source of 
comfort to me. 
1 2 3 4 5 6 7 SO 
 6.  My friends really try to help me. 1 2 3 4 5 6 7 Fri 
 7. I can count on my friends when things go wrong. 1 2 3 4 5 6 7 Fri 
 8. I can talk about my problems with my family. 1 2 3 4 5 6 7 Fam 
 9. I have friends with whom I can share my joys 
and sorrows. 
1 2 3 4 5 6 7 Fri 
10. There is a special person in my life who cares 
about my feelings. 
1 2 3 4 5 6 7 SO 
11. My family is willing to help me make decisions. 1 2 3 4 5 6 7 Fam 
12. I can talk about my problems with my friends. 1 2 3 4 5 6 7 Fri 
 
 
The items tended to divide into factor groups relating to the source of the social support, namely family 
(Fam), friends (Fri) or significant other (SO). 
 
 
 
 
 
 
 
 
  
 
 
MASTER CHART 
 
 
s.no age sex educ ses religion occup marietal 
status
spouse.s fam.type familyh/o pasth/o age at diag mode of trans HIV 
stage
CD4 
count
treatment treat.regimen duration of treat comorbidity opp.infec psych.illness types of illness severity MOCA Adherence mpss kps
1 42 2 2 4 3 2 1 1 1 2 2 35 1 1 1 2 1 2 1 6 1 24 2 2 1
2 25 1 4 3 1 4 2 2 2 2 24 1 1 1 2 1 1 4 6 2 1 3 29 1 1 1
3 40 2 3 4 1 2 1 1 1 2 2 27 1 1 1 2 5 4 4 6 2 1 1 24 1 2 1
4 37 2 2 4 1 2 1 2 1 2 2 25 6 1 1 2 1 4 4 6 1 22 1 2 1
5 39 2 2 4 1 3 1 1 1 2 2 29 1 1 1 2 3 4 4 6 2 1 1 18 1 3 1
6 44 2 2 4 1 2 3 1 1 2 2 31 1 1 2 2 1 4 4 6 1 24 1 2 1
7 37 1 2 5 1 2 1 1 1 2 2 25 6 1 2 2 3 4 4 6 1 23 1 2 1
8 42 1 2 4 1 4 1 1 2 2 2 28 1 2 3 2 1 4 6 6 2 3 3 15 2 1 2
9 17 1 3 4 1 2 2 2 2 2 8 5 3 3 2 3 3 4 1 1 26 2 2 1
10 43 2 2 4 3 2 3 1 1 2 2 42 1 3 3 2 1 1 4 1 2 1 1 27 1 2 1
11 34 2 3 2 3 2 1 2 1 2 2 24 4 1 1 2 1 3 4 6 1 27 1 3 1
12 24 3 2 5 1 1 2 2 2 1 20 1 2 3 2 1 2 4 3 2 3 3 23 3 1 2
13 34 1 2 3 1 4 2 1 2 2 33 1 1 1 2 1 2 4 6 2 3 3 28 1 3 1
14 60 2 2 5 1 2 3 1 2 2 2 60 4 1 2 2 1 1 4 6 1 23 1 3 1
15 45 2 2 4 1 2 1 1 1 2 2 35 1 1 1 2 4 3 4 6 2 2 1 25 1 2 2
16 53 1 4 2 1 4 1 1 1 1 2 43 1 1 1 2 1 3 1 6 1 27 1 3 1
17 50 1 2 4 1 4 1 2 1 2 2 47 1 1 2 2 1 2 4 6 1 25 1 1 1
18 51 2 2 4 1 1 3 1 2 2 2 36 1 1 1 2 3 4 4 6 1 21 1 3 1
19 30 1 4 2 1 5 2 2 2 2 27 1 1 1 2 1 2 4 6 2 2 1 29 1 2 1
20 31 1 5 2 1 4 2 2 2 2 30 1 3 3 2 1 1 2 1 2 1 2 26 1 2 1
21 25 1 2 4 1 3 2 2 1 2 12 5 3 4 2 1 2 4 1 2 1 2 22 2 1 2
22 63 2 2 5 1 2 1 2 2 2 2 62 6 1 2 2 1 2 4 6 1 22 1 3 1
23 38 1 2 4 1 2 4 1 1 1 2 33 1 1 2 2 3 3 4 6 1 24 1 2 1
24 35 2 1 4 1 2 1 2 1 2 2 25 4 1 2 2 1 2 4 6 1 26 2 3 1
25 41 1 2 5 1 2 1 2 1 2 2 38 1 1 1 2 1 2 4 6 1 25 1 3 1
26 50 1 3 4 1 3 1 2 2 1 2 42 4 1 1 2 3 3 1 6 1 24 1 3 1
27 38 2 2 4 1 2 3 1 1 2 2 28 1 1 1 2 3 3 4 6 1 24 1 3 1
28 49 1 3 5 1 2 1 2 1 2 2 38 4 1 3 2 1 3 4 6 1 24 2 3 1
29 39 1 2 4 1 4 1 1 1 2 2 28 1 4 4 2 1 4 4 1 2 1 2 22 3 2 2
30 43 2 2 3 1 2 3 1 2 2 2 37 1 1 1 2 1 2 4 6 1 26 1 3 1
31 56 2 2 5 3 1 3 1 2 2 2 50 1 1 1 2 3 2 7 6 1 22 1 3 1
32 37 1 3 4 3 2 1 2 2 1 2 36 1 1 1 2 1 1 1 6 2 2 26 1 3 1
33 55 2 2 5 1 2 1 1 1 2 2 50 1 1 1 2 1 2 2 6 2 2 25 1 3 1
34 66 1 3 4 1 1 1 1 1 2 2 60 1 1 3 2 3 3 4 6 1 23 3 3 2
35 43 2 1 2 1 2 1 1 1 2 2 39 1 1 4 2 1 2 4 6 1 24 2 3 1
36 41 1 2 5 1 3 1 1 2 2 2 38 1 1 4 2 1 2 4 2 1 26 2 3 1
37 48 1 1 5 1 4 1 1 1 2 2 36 6 1 2 2 3 3 4 6 2 1 1 24 1 3 1
38 41 1 2 4 1 3 1 1 1 2 2 40 1 2 2 2 1 1 4 6 2 1 1 26 3 1 2
39 51 1 3 2 1 3 1 1 1 2 2 33 6 1 3 2 2 4 8 6 2 1 2 23 2 3 3
40 50 2 3 4 1 2 3 1 2 2 2 40 1 1 1 2 1 3 2 6 1 25 1 3 2
41 29 1 4 4 1 4 2 1 2 2 28 6 1 3 2 1 2 4 6 1 30 1 3 1
42 32 1 1 5 1 4 1 2 1 1 2 30 2 1 1 2 1 2 4 6 1 25 3 2 1
43 51 2 3 4 1 2 1 1 2 2 2 43 1 1 1 2 1 3 1 6 2 1 1 24 1 3 1
44 45 1 4 3 1 1 2 1 2 2 32 4 1 1 2 1 4 4 6 1 20 1 3 1
45 40 2 1 4 1 2 1 1 1 2 2 38 1 1 1 2 1 2 4 6 1 20 1 3 1
46 61 1 3 4 1 1 1 2 2 2 2 50 1 1 3 2 3 4 4 6 1 25 1 3 2
47 52 1 3 4 1 4 1 2 2 2 2 41 1 1 1 2 3 3 4 6 1 24 2 3 1
48 43 2 2 5 1 1 2 3 2 2 24 1 1 1 2 7 4 4 6 2 5 1 14 3 1 3
49 34 1 3 4 1 3 2 2 1 2 34 1 1 1 2 1 1 4 6 2 1 1 23 2 3 1
50 57 2 1 3 1 1 3 2 2 2 2 55 4 2 3 2 1 2 4 2 1 24 2 3 1
51 55 1 1 5 1 2 1 1 2 2 2 55 1 4 4 2 1 1 9 6 2 3 2 22 2 3 2
52 65 2 1 5 1 1 3 1 2 2 2 55 1 1 2 2 1 4 4 6 1 23 1 3 1
53 38 2 1 5 1 2 1 1 1 2 2 34 1 1 1 2 1 2 4 6 1 26 2 3 1
54 44 1 2 4 1 4 1 1 1 2 2 40 1 1 3 2 1 2 4 6 1 27 2 3 1
55 53 1 2 3 1 4 1 2 2 2 2 49 1 1 3 2 3 2 2 6 1 26 2 3 1
56 35 2 2 4 1 2 1 2 1 2 2 25 4 1 1 2 1 3 4 6 1 28 1 2 1
57 31 1 2 4 1 4 2 2 1 2 27 1 3 4 2 6 1 1 1 2 1 2 22 3 1 3
58 31 2 2 5 1 2 1 2 1 2 2 19 1 1 1 2 5 2 4 6 1 26 1 3 1
59 42 2 2 4 1 3 3 1 1 2 2 29 1 1 1 2 1 2 4 6 1 28 1 3 1
60 34 2 3 4 1 2 1 1 1 2 2 26 1 1 1 2 3 3 4 6 1 28 1 3 1
61 34 2 2 5 3 2 1 1 1 1 2 28 1 1 1 2 1 1 4 6 2 1 2 24 1 3 1
62 58 1 2 5 1 3 1 1 2 1 2 45 1 1 1 2 1 4 4 6 2 1 2 13 2 1 2
63 26 3 2 5 1 2 2 1 2 2 26 1 3 4 2 1 1 4 6 2 2 24 2 3 1
64 39 2 4 4 1 2 3 1 3 2 2 15 1 1 2 2 5 4 4 6 1 22 1 1 1
65 46 1 2 5 1 1 4 2 1 2 2 34 1 2 4 2 1 4 4 2 2 6 3 18 3 2 3
66 41 1 4 3 1 4 1 1 1 1 2 32 1 1 2 2 1 3 1 6 1 26 1 3 1
67 52 2 2 3 1 2 1 1 1 2 2 42 1 1 1 2 3 4 3 6 1 24 1 3 1
68 46 2 2 5 1 2 3 2 1 1 2 38 1 1 1 2 1 3 4 6 1 26 2 3 1
69 65 2 1 5 1 1 3 1 1 2 2 57 1 1 2 2 1 3 4 6 1 24 1 3 1
70 32 1 4 3 1 4 4 2 2 2 2 31 6 3 3 2 1 1 4 1 2 2 1 24 2 3 1
71 55 1 2 5 1 2 1 2 2 1 2 54 6 1 2 2 1 2 4 6 2 1 1 24 1 3 1
72 42 1 5 3 1 5 1 1 1 2 2 31 6 1 1 2 3 3 4 6 1 28 1 3 1
73 39 2 2 5 1 2 1 1 2 2 2 28 6 1 1 2 1 4 4 6 1 27 1 3 1
74 29 1 2 5 1 2 2 2 1 2 27 6 1 1 2 1 1 4 6 2 1 2 26 3 3 1
75 38 2 2 4 2 4 3 2 1 2 2 38 6 3 4 2 1 1 4 2 2 1 3 23 1 3 2
76 45 2 1 5 3 1 2 2 2 2 45 6 4 4 2 1 1 4 1 2 1 2 22 2 2 3
77 32 1 4 4 1 4 1 1 1 2 2 23 1 1 2 2 3 2 4 6 1 29 2 3 1
78 40 2 2 5 1 2 3 1 1 1 2 39 1 1 1 2 1 1 4 6 2 2 1 26 1 3 1
79 38 1 2 4 1 4 1 1 2 2 2 28 1 2 3 2 3 3 4 3 1 24 2 2 1
80 44 2 2 5 2 2 3 1 1 2 2 30 1 2 3 2 3 4 4 4 2 1 2 20 2 1 2
81 32 1 3 4 1 2 1 2 2 2 1 32 1 1 2 2 1 1 4 6 2 3 3 28 2 2 1
82 32 1 3 3 1 3 1 1 2 2 2 26 6 1 3 2 3 3 4 6 2 3 2 22 2 3 1
83 37 2 3 4 3 3 1 1 2 2 2 32 1 1 1 2 3 3 4 6 1 24 2 2 1
84 40 2 2 5 1 2 1 1 1 2 2 29 6 1 1 2 3 3 4 6 1 20 1 3 1
85 38 1 2 4 3 3 1 1 2 2 1 30 6 1 1 2 3 3 4 6 1 22 1 3 1
86 42 1 2 4 1 2 1 2 1 2 2 32 1 1 1 2 3 3 4 6 1 22 2 2 2
87 18 1 2 5 1 1 2 2 1 2 5 5 1 1 2 5 4 4 6 2 5 2 13 1 3 1
88 30 2 2 4 1 2 1 1 2 2 2 23 1 1 1 2 1 3 4 6 1 25 1 3 1
89 37 2 4 3 1 2 1 1 2 2 2 26 1 1 1 2 1 3 4 6 1 26 1 3 1
90 42 1 5 2 1 5 1 1 1 2 2 31 6 1 1 2 3 3 1 6 1 30 1 3 1
91 39 2 2 5 1 2 1 1 2 2 2 28 6 1 1 2 1 4 4 6 1 24 1 3 1
92 19 1 2 5 1 2 2 3 2 2 3 5 1 1 2 3 4 4 6 1 20 1 1 1
93 40 2 2 5 1 1 3 1 1 2 2 29 1 1 1 2 3 4 4 6 2 1 1 22 2 3 2
94 38 1 3 3 1 4 1 2 1 2 2 36 6 1 2 2 1 2 4 6 2 1 2 23 1 3 1
95 36 1 2 4 1 3 1 1 1 1 2 30 1 1 4 2 5 3 4 2 2 2 1 23 3 2 3
96 30 2 2 4 1 2 1 2 2 2 2 24 5 4 4 2 5 3 4 3 2 1 1 24 3 2 2
97 46 2 1 5 1 2 1 1 1 2 2 38 1 4 4 2 3 3 1 1 2 2 1 25 2 2 2
98 44 1 4 4 1 1 1 2 1 2 2 44 1 4 4 2 1 1 4 1 2 3 3 20 1 2 3
99 42 1 2 4 1 3 1 2 1 2 2 32 6 1 1 2 3 3 4 6 1 28 1 2 1
100 18 1 2 5 1 1 2 2 1 2 5 6 1 1 2 5 4 4 6 2 5 2 15 1 3 2
101 37 2 2 4 1 2 1 1 2 2 2 23 1 1 1 2 1 3 5 6 1 26 1 3 1
102 30 2 4 4 1 2 1 1 1 2 2 26 1 1 1 2 3 3 4 6 1 24 1 3 1
103 42 1 2 3 1 4 1 2 2 2 2 40 1 4 4 2 1 2 4 6 2 3 2 24 3 3 2
104 33 1 3 4 2 3 4 2 3 1 2 24 1 2 3 2 1 3 4 5 2 6 2 28 2 1 1
105 45 1 1 4 1 2 1 1 2 2 2 28 2 2 2 2 1 4 3 2 2 4 1 24 2 2 1
106 28 2 1 4 2 1 1 1 1 2 2 26 1 1 1 2 1 2 4 6 2 4 2 25 1 2 1
107 30 3 2 5 1 1 2 1 2 2 25 1 1 2 2 1 3 4 6 2 3 2 26 2 2 1
108 41 1 1 4 3 2 4 1 1 1 2 30 1 1 1 2 1 4 1 6 2 3 2 22 2 2 1
109 52 1 1 5 1 1 1 2 2 2 2 32 1 1 1 2 1 4 3 6 1 20 1 2 1
